AU2020232350A1 - Methods for treating or preventing heart failure and reducing risk of heart failure - Google Patents
Methods for treating or preventing heart failure and reducing risk of heart failure Download PDFInfo
- Publication number
- AU2020232350A1 AU2020232350A1 AU2020232350A AU2020232350A AU2020232350A1 AU 2020232350 A1 AU2020232350 A1 AU 2020232350A1 AU 2020232350 A AU2020232350 A AU 2020232350A AU 2020232350 A AU2020232350 A AU 2020232350A AU 2020232350 A1 AU2020232350 A1 AU 2020232350A1
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- isopentylcyclohexanecarbonylamino
- mant
- dimethylthiopropionate
- ant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 265
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 54
- 230000002861 ventricular Effects 0.000 claims abstract description 123
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 66
- 206010052337 Diastolic dysfunction Diseases 0.000 claims abstract description 66
- 206010071436 Systolic dysfunction Diseases 0.000 claims abstract description 56
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims abstract description 26
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 293
- 239000003795 chemical substances by application Substances 0.000 claims description 286
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims description 279
- 239000003112 inhibitor Substances 0.000 claims description 222
- 150000003839 salts Chemical class 0.000 claims description 215
- 230000000694 effects Effects 0.000 claims description 159
- 230000002829 reductive effect Effects 0.000 claims description 117
- 102100032153 Adenylate cyclase type 8 Human genes 0.000 claims description 114
- 101000775481 Homo sapiens Adenylate cyclase type 8 Proteins 0.000 claims description 114
- UBJMOTPQBCKENW-WJOKGBTCSA-N n-[(1r)-1-(3-cyclopropyloxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)C=2C=C(C(F)=CC=2)C(F)(F)F)C=2C=C(OC3CC3)C(F)=CC=2)=C1 UBJMOTPQBCKENW-WJOKGBTCSA-N 0.000 claims description 101
- 102100032156 Adenylate cyclase type 9 Human genes 0.000 claims description 77
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical group C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 claims description 67
- SOJUSNIBPPMLCC-UHFFFAOYSA-N 2-amino-7-(furan-2-yl)-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1C2=NC(N)=NC=C2C(=O)CC1C1=CC=CO1 SOJUSNIBPPMLCC-UHFFFAOYSA-N 0.000 claims description 60
- 102100039677 Adenylate cyclase type 1 Human genes 0.000 claims description 57
- 102100032157 Adenylate cyclase type 10 Human genes 0.000 claims description 57
- 102100039675 Adenylate cyclase type 2 Human genes 0.000 claims description 57
- 102100039660 Adenylate cyclase type 4 Human genes 0.000 claims description 57
- 102100032161 Adenylate cyclase type 5 Human genes 0.000 claims description 57
- 102100032158 Adenylate cyclase type 6 Human genes 0.000 claims description 57
- 102100032152 Adenylate cyclase type 7 Human genes 0.000 claims description 57
- 101000959343 Homo sapiens Adenylate cyclase type 1 Proteins 0.000 claims description 57
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 claims description 57
- 101000959347 Homo sapiens Adenylate cyclase type 2 Proteins 0.000 claims description 57
- 101000959328 Homo sapiens Adenylate cyclase type 3 Proteins 0.000 claims description 57
- 101000959333 Homo sapiens Adenylate cyclase type 4 Proteins 0.000 claims description 57
- 101000775478 Homo sapiens Adenylate cyclase type 5 Proteins 0.000 claims description 57
- 101000775489 Homo sapiens Adenylate cyclase type 6 Proteins 0.000 claims description 57
- 101000775483 Homo sapiens Adenylate cyclase type 7 Proteins 0.000 claims description 57
- 229950004181 dalcetrapib Drugs 0.000 claims description 56
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims description 53
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 claims description 51
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 claims description 50
- 229950004514 torcetrapib Drugs 0.000 claims description 50
- BHKIPHICFOJGLD-HOFKKMOUSA-N (5s)-4-cyclohexyl-2-cyclopentyl-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCCCC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C1CCCC1 BHKIPHICFOJGLD-HOFKKMOUSA-N 0.000 claims description 49
- 229950000285 anacetrapib Drugs 0.000 claims description 48
- 229950000005 evacetrapib Drugs 0.000 claims description 48
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 claims description 48
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 46
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 46
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 46
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 46
- 229950004285 obicetrapib Drugs 0.000 claims description 44
- VUGWFHHXRWKZKD-UHFFFAOYSA-N 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1=CC(OC)=CC=C1C1CC2=NC(N)=NC=C2C(=O)C1 VUGWFHHXRWKZKD-UHFFFAOYSA-N 0.000 claims description 36
- QNFZGNPBBNOUBH-UHFFFAOYSA-N 2-amino-7-phenyl-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1C2=NC(N)=NC=C2C(=O)CC1C1=CC=CC=C1 QNFZGNPBBNOUBH-UHFFFAOYSA-N 0.000 claims description 36
- SSBIOMBKWGPZQK-UHFFFAOYSA-N 2-amino-7-thiophen-2-yl-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1C2=NC(N)=NC=C2C(=O)CC1C1=CC=CS1 SSBIOMBKWGPZQK-UHFFFAOYSA-N 0.000 claims description 36
- UKHMZCMKHPHFOT-UHFFFAOYSA-N 9-(tetrahydrofuryl)adenine Chemical group C1=NC=2C(N)=NC=NC=2N1C1CCCO1 UKHMZCMKHPHFOT-UHFFFAOYSA-N 0.000 claims description 36
- 230000008901 benefit Effects 0.000 claims description 35
- OCNBSSLDAIWTKS-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-n,n-bis(cyclopropylmethyl)-8-methylquinolin-2-amine Chemical compound C1CC1CN(CC1CC1)C=1N=C2C(C)=CC=CC2=CC=1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OCNBSSLDAIWTKS-UHFFFAOYSA-N 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 31
- YGEIMSMISRCBFF-UHFFFAOYSA-M 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium;chloride Chemical compound [Cl-].C1=CC(Cl)=CC=C1C([N+]1=CN(CC(OCC=2C(=CC(Cl)=CC=2)Cl)C=2C(=CC(Cl)=CC=2)Cl)C=C1)C1=CC=C(Cl)C=C1 YGEIMSMISRCBFF-UHFFFAOYSA-M 0.000 claims description 24
- YZOFLYUAQDJWKV-UHFFFAOYSA-N 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC(C=C(C#N)C#N)=CC(O)=C1O YZOFLYUAQDJWKV-UHFFFAOYSA-N 0.000 claims description 24
- KLGSQPHEMZCRTF-UHFFFAOYSA-N 2-amino-7-(4-chlorophenyl)-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1C2=NC(N)=NC=C2C(=O)CC1C1=CC=C(Cl)C=C1 KLGSQPHEMZCRTF-UHFFFAOYSA-N 0.000 claims description 24
- DSPRYHPLXXUNHS-XNIJJKJLSA-N 3'-MANT-GTP Chemical compound CNC1=CC=CC=C1C(=O)O[C@H]1[C@@H](O)[C@H](N2C3=C(C(N=C(N)N3)=O)N=C2)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(O)=O DSPRYHPLXXUNHS-XNIJJKJLSA-N 0.000 claims description 24
- PDWZXKSZLRVSEH-UHFFFAOYSA-N 6-chloro-4-n-cyclopropyl-4-n-(thiophen-2-ylmethyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(Cl)=CC(N(CC=2SC=CC=2)C2CC2)=N1 PDWZXKSZLRVSEH-UHFFFAOYSA-N 0.000 claims description 24
- KTJWHJNBTXITCB-UHFFFAOYSA-N 9-cyclopentylpurin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CCCC1 KTJWHJNBTXITCB-UHFFFAOYSA-N 0.000 claims description 24
- AJMDRSJHCYQPQI-UHFFFAOYSA-N 9-cyclopentylpurin-6-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=NC=2C(N)=NC=NC=2N1C1CCCC1 AJMDRSJHCYQPQI-UHFFFAOYSA-N 0.000 claims description 24
- 101100021579 Homo sapiens L1RE1 gene Proteins 0.000 claims description 24
- 102100031764 LINE-1 retrotransposable element ORF1 protein Human genes 0.000 claims description 24
- 101100075458 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LRE1 gene Proteins 0.000 claims description 24
- 101100022768 Schizosaccharomyces pombe (strain 972 / ATCC 24843) med18 gene Proteins 0.000 claims description 24
- DSFVPALDDWRTFF-DIBLVGDCSA-N TNP-ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O1)N2C=3N=CN=C(C=3N=C2)N)C21C([N+]([O-])=O)C=C([N+]([O-])=O)C=C2[N+]([O-])=O DSFVPALDDWRTFF-DIBLVGDCSA-N 0.000 claims description 24
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 24
- ZJGUOEYCABTFNH-DSYKOEDSSA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] [hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound C1[C@H](OP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJGUOEYCABTFNH-DSYKOEDSSA-N 0.000 claims description 24
- 239000001226 triphosphate Substances 0.000 claims description 24
- 229960003636 vidarabine Drugs 0.000 claims description 24
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 23
- 102400000739 Corticotropin Human genes 0.000 claims description 23
- 101800000414 Corticotropin Proteins 0.000 claims description 23
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 23
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 23
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 23
- 229960000258 corticotropin Drugs 0.000 claims description 23
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims description 23
- NZOJDGVSAOPCON-UHFFFAOYSA-N propanehydrazide Chemical compound C[CH]C(=O)NN NZOJDGVSAOPCON-UHFFFAOYSA-N 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 18
- 210000003016 hypothalamus Anatomy 0.000 claims description 17
- FFHPXOJTVQDVMO-DSYKOEDSSA-N (2r,3s,5r)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-ol Chemical compound C1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FFHPXOJTVQDVMO-DSYKOEDSSA-N 0.000 claims description 12
- NFGZMOICZSFFLB-DSYKOEDSSA-N 2',5'-dideoxy-adenosine 3'-monophosphate Chemical compound C1[C@H](OP(O)(O)=O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NFGZMOICZSFFLB-DSYKOEDSSA-N 0.000 claims description 12
- MGLPWFCQGUXOCH-DSYKOEDSSA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] phosphono hydrogen phosphate Chemical compound C1[C@H](OP(O)(=O)OP(O)(O)=O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MGLPWFCQGUXOCH-DSYKOEDSSA-N 0.000 claims description 12
- OVRLABAFXJPIMU-UHFFFAOYSA-N 1-(2-ethylbutyl)-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC(CC)CC)CCCCC1 OVRLABAFXJPIMU-UHFFFAOYSA-N 0.000 claims description 8
- CWOUDBOBZZCQFG-UHFFFAOYSA-N 1-(2-ethylbutyl)-n-[2-[[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl]disulfanyl]phenyl]cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(SSC=2C(=CC=CC=2)NC(=O)C2(CC(CC)CC)CCCCC2)C=1NC(=O)C1(CC(CC)CC)CCCCC1 CWOUDBOBZZCQFG-UHFFFAOYSA-N 0.000 claims description 8
- INKBUBAEIMNSIG-UHFFFAOYSA-N 1-(2-methylpropyl)-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC(C)C)CCCCC1 INKBUBAEIMNSIG-UHFFFAOYSA-N 0.000 claims description 8
- OAHGZDNPTGFOGR-UHFFFAOYSA-N 1-(3-methylbutyl)-n-[2-(oxolan-2-ylmethyldisulfanyl)phenyl]cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(SSCC2OCCC2)C=1NC(=O)C1(CCC(C)C)CCCCC1 OAHGZDNPTGFOGR-UHFFFAOYSA-N 0.000 claims description 8
- RPOWLQXTRJDTQA-UHFFFAOYSA-N 1-butyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCCC)CCCCC1 RPOWLQXTRJDTQA-UHFFFAOYSA-N 0.000 claims description 8
- HNJZDNMUVSELCB-UHFFFAOYSA-N 1-ethyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC)CCCCC1 HNJZDNMUVSELCB-UHFFFAOYSA-N 0.000 claims description 8
- GIBQUYMCEXFBRU-UHFFFAOYSA-N 1-propyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCC)CCCCC1 GIBQUYMCEXFBRU-UHFFFAOYSA-N 0.000 claims description 8
- HKFQYGGDMAJXBG-UHFFFAOYSA-N CC(C)(C)C(NC1=CC(C(F)(F)F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)(C)C(NC1=CC(C(F)(F)F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O HKFQYGGDMAJXBG-UHFFFAOYSA-N 0.000 claims description 8
- CVPVIZFFXPMLPP-UHFFFAOYSA-N CC(C)(C)C([O-])=[S+]C(C(NC(C1(CC2CC2)CCCCC1)=O)=C1)=CC(Cl)=C1Cl Chemical compound CC(C)(C)C([O-])=[S+]C(C(NC(C1(CC2CC2)CCCCC1)=O)=C1)=CC(Cl)=C1Cl CVPVIZFFXPMLPP-UHFFFAOYSA-N 0.000 claims description 8
- RYLPLLYYUQQNDQ-UHFFFAOYSA-N CC(C)(C)C([O-])=[S+]C(C(NC(C1(CC2CCCCC2)CCCCC1)=O)=C1)=CC(Cl)=C1Cl Chemical compound CC(C)(C)C([O-])=[S+]C(C(NC(C1(CC2CCCCC2)CCCCC1)=O)=C1)=CC(Cl)=C1Cl RYLPLLYYUQQNDQ-UHFFFAOYSA-N 0.000 claims description 8
- KOCJXXQFYRJDNP-UHFFFAOYSA-N CC(C)(C)C([O-])=[S+]C(C(NC(C1(CCCCC1)C1CC1)=O)=C1)=CC(Cl)=C1Cl Chemical compound CC(C)(C)C([O-])=[S+]C(C(NC(C1(CCCCC1)C1CC1)=O)=C1)=CC(Cl)=C1Cl KOCJXXQFYRJDNP-UHFFFAOYSA-N 0.000 claims description 8
- ACKNTCOLTOCTLM-UHFFFAOYSA-N CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)C)[O-])=O Chemical compound CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)C)[O-])=O ACKNTCOLTOCTLM-UHFFFAOYSA-N 0.000 claims description 8
- DNJXSUYXQCYBCA-UHFFFAOYSA-N CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1)CCN1C(C)=O)[O-])=O Chemical compound CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1)CCN1C(C)=O)[O-])=O DNJXSUYXQCYBCA-UHFFFAOYSA-N 0.000 claims description 8
- MSHODUWEWWGOOH-UHFFFAOYSA-N CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O Chemical compound CC(C)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O MSHODUWEWWGOOH-UHFFFAOYSA-N 0.000 claims description 8
- JKBVSRJVVFLCPL-UHFFFAOYSA-N CC(C)CCC1(CCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C)CCC1(CCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O JKBVSRJVVFLCPL-UHFFFAOYSA-N 0.000 claims description 8
- DKZDFCHPASCABE-UHFFFAOYSA-N CC(C)CCC1(CCCC1)C(NC(C=CC=C1)=C1[S+]=C(C)[O-])=O Chemical compound CC(C)CCC1(CCCC1)C(NC(C=CC=C1)=C1[S+]=C(C)[O-])=O DKZDFCHPASCABE-UHFFFAOYSA-N 0.000 claims description 8
- JGVQGOPOFPCNSG-UHFFFAOYSA-N CC(C)CCC1(CCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O JGVQGOPOFPCNSG-UHFFFAOYSA-N 0.000 claims description 8
- MSODXWAILLEOKQ-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC=C1Cl)=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC=C1Cl)=O MSODXWAILLEOKQ-UHFFFAOYSA-N 0.000 claims description 8
- KBTBRBNHQMTOLQ-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC=C1F)=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC=C1F)=O KBTBRBNHQMTOLQ-UHFFFAOYSA-N 0.000 claims description 8
- ODAVTSIXKOFLKJ-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C=C(C)C=C1)=C1[S+]=C(C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C=C(C)C=C1)=C1[S+]=C(C)[O-])=O ODAVTSIXKOFLKJ-UHFFFAOYSA-N 0.000 claims description 8
- UZOHYZMLIHMTJD-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C=CC=C1)=C1[S+]=C(NC1=CC=CC=C1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C=CC=C1)=C1[S+]=C(NC1=CC=CC=C1)[O-])=O UZOHYZMLIHMTJD-UHFFFAOYSA-N 0.000 claims description 8
- YXXTVAUUIMEPBK-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=C(CO[S+]=C(C)[O-])C=CC=C1)=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=C(CO[S+]=C(C)[O-])C=CC=C1)=O YXXTVAUUIMEPBK-UHFFFAOYSA-N 0.000 claims description 8
- FNBFPIZRTHRSER-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC(C#N)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC(C#N)=CC=C1[S+]=C(C(C)(C)C)[O-])=O FNBFPIZRTHRSER-UHFFFAOYSA-N 0.000 claims description 8
- XOAGNGMPTCKMHJ-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC(C(F)(F)F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC(C(F)(F)F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O XOAGNGMPTCKMHJ-UHFFFAOYSA-N 0.000 claims description 8
- OZQDOUAJOHKJCA-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC(Cl)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC(Cl)=CC=C1[S+]=C(C(C)(C)C)[O-])=O OZQDOUAJOHKJCA-UHFFFAOYSA-N 0.000 claims description 8
- GUXBXXWDWQQUTM-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC(F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC(F)=CC=C1[S+]=C(C(C)(C)C)[O-])=O GUXBXXWDWQQUTM-UHFFFAOYSA-N 0.000 claims description 8
- VPEOYCNRKMFMLR-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC([N+]([O-])=O)=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC([N+]([O-])=O)=CC=C1[S+]=C(C(C)(C)C)[O-])=O VPEOYCNRKMFMLR-UHFFFAOYSA-N 0.000 claims description 8
- ANBQCGTWXRIKMR-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical group CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O ANBQCGTWXRIKMR-UHFFFAOYSA-N 0.000 claims description 8
- SOWBEPLMRWTJBB-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)O)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)O)[O-])=O SOWBEPLMRWTJBB-UHFFFAOYSA-N 0.000 claims description 8
- MNAGYMNOTXQYDU-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)C)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)C)[O-])=O MNAGYMNOTXQYDU-UHFFFAOYSA-N 0.000 claims description 8
- LLTZYJKWBPMPER-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1=CC=CC=C1)NC(C)=O)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1=CC=CC=C1)NC(C)=O)[O-])=O LLTZYJKWBPMPER-UHFFFAOYSA-N 0.000 claims description 8
- CBNQKLSJMCHBPA-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CCC(N)=O)NC(C)=O)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CCC(N)=O)NC(C)=O)[O-])=O CBNQKLSJMCHBPA-UHFFFAOYSA-N 0.000 claims description 8
- MVVQXGJQXHQGDM-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1=CC=CC=C1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1=CC=CC=C1)[O-])=O MVVQXGJQXHQGDM-UHFFFAOYSA-N 0.000 claims description 8
- XIJOLBVDKFPIOI-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1=CC=CN=C1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1=CC=CN=C1)[O-])=O XIJOLBVDKFPIOI-UHFFFAOYSA-N 0.000 claims description 8
- GUOOTJJNRZQQTN-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1CC1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1CC1)[O-])=O GUOOTJJNRZQQTN-UHFFFAOYSA-N 0.000 claims description 8
- XBPUVLUVMKFXBX-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1CCCCC1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C1CCCCC1)[O-])=O XBPUVLUVMKFXBX-UHFFFAOYSA-N 0.000 claims description 8
- JNXMVVJSQRYOOU-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(CCCCC(O)=O)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(CCCCC(O)=O)[O-])=O JNXMVVJSQRYOOU-UHFFFAOYSA-N 0.000 claims description 8
- CVQJFMBVQHREPR-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(CCl)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(CCl)[O-])=O CVQJFMBVQHREPR-UHFFFAOYSA-N 0.000 claims description 8
- QWHBBXLECJTCNF-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O QWHBBXLECJTCNF-UHFFFAOYSA-N 0.000 claims description 8
- HJGCFZMAWOMOPH-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC1=CC=CC=C1)[O-])=O Chemical compound CC(C)CCC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC1=CC=CC=C1)[O-])=O HJGCFZMAWOMOPH-UHFFFAOYSA-N 0.000 claims description 8
- OPLQLEIOUMHUBS-UHFFFAOYSA-N CC(C)CCC1(CCCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C)CCC1(CCCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O OPLQLEIOUMHUBS-UHFFFAOYSA-N 0.000 claims description 8
- MXSZWTOZVUPPLL-UHFFFAOYSA-N CC(C1CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C1CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O MXSZWTOZVUPPLL-UHFFFAOYSA-N 0.000 claims description 8
- XQEQRMFVNBATRX-UHFFFAOYSA-N CC1(CCCCC1)C(NC1=CC=CC=C1[SH](C(O)=S)C1=CC=CC=C1)=O Chemical compound CC1(CCCCC1)C(NC1=CC=CC=C1[SH](C(O)=S)C1=CC=CC=C1)=O XQEQRMFVNBATRX-UHFFFAOYSA-N 0.000 claims description 8
- BERVSBUQADEMLF-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC(C=CC=C1)=C1[S+]=C(C)[O-])=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC(C=CC=C1)=C1[S+]=C(C)[O-])=O BERVSBUQADEMLF-UHFFFAOYSA-N 0.000 claims description 8
- LZIPDZWCPJYOBJ-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC1=C(CO[S+]=C(C)[O-])C=CC=C1)=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC1=C(CO[S+]=C(C)[O-])C=CC=C1)=O LZIPDZWCPJYOBJ-UHFFFAOYSA-N 0.000 claims description 8
- XOKJFUWANWXKCC-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)C)[O-])=O XOKJFUWANWXKCC-UHFFFAOYSA-N 0.000 claims description 8
- MJXHIDJMYXDFND-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1)CCN1C(C)=O)[O-])=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(CC1)CCN1C(C)=O)[O-])=O MJXHIDJMYXDFND-UHFFFAOYSA-N 0.000 claims description 8
- CJNPAUBVMROKSU-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(COC(C=C1)=CC=C1Cl)[O-])=O CJNPAUBVMROKSU-UHFFFAOYSA-N 0.000 claims description 8
- BXNBALVIOLYEKH-UHFFFAOYSA-N CCC([O-])=[S+]C(C=CC=C1)=C1NC(C1(CCC(C)C)CCCCC1)=O Chemical compound CCC([O-])=[S+]C(C=CC=C1)=C1NC(C1(CCC(C)C)CCCCC1)=O BXNBALVIOLYEKH-UHFFFAOYSA-N 0.000 claims description 8
- WZYJCVDMLLFVPO-UHFFFAOYSA-N n-[4,5-dichloro-2-[[4,5-dichloro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl]disulfanyl]phenyl]-1-(3-methylbutyl)cyclohexane-1-carboxamide Chemical compound C=1C(Cl)=C(Cl)C=C(SSC=2C(=CC(Cl)=C(Cl)C=2)NC(=O)C2(CCC(C)C)CCCCC2)C=1NC(=O)C1(CCC(C)C)CCCCC1 WZYJCVDMLLFVPO-UHFFFAOYSA-N 0.000 claims description 8
- 101000775499 Homo sapiens Adenylate cyclase type 9 Proteins 0.000 claims 14
- NWYDOIAZNDEBBH-UHFFFAOYSA-N CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)O)[O-])=O Chemical compound CCC(CC)CC1(CCCCC1)C(NC1=CC=CC=C1[S+]=C(C(C)(C)O)[O-])=O NWYDOIAZNDEBBH-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 abstract description 77
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 432
- 235000002639 sodium chloride Nutrition 0.000 description 178
- 241000699670 Mus sp. Species 0.000 description 81
- 101710194238 Adenylate cyclase type 9 Proteins 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 32
- 238000003556 assay Methods 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 23
- -1 (2R)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1- methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2-ethylpyrrolidin-1-yl Chemical group 0.000 description 21
- 108700028369 Alleles Proteins 0.000 description 19
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 18
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 208000024172 Cardiovascular disease Diseases 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 16
- 208000008253 Systolic Heart Failure Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 230000000923 atherogenic effect Effects 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 230000007211 cardiovascular event Effects 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000001177 diphosphate Substances 0.000 description 12
- RTRIXVOSRYRSBP-VXKWHMMOSA-N n-[(1s,2s)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine Chemical compound N([C@H]1CCC[C@H]1C=1C=CC=CC=1)C1=NCCCCCCCCCCC1 RTRIXVOSRYRSBP-VXKWHMMOSA-N 0.000 description 12
- 102000054765 polymorphisms of proteins Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- JUXTWKYSGNVPGS-UHFFFAOYSA-N 7,8-dihydro-6h-quinazolin-5-one Chemical class C1=NC=C2C(=O)CCCC2=N1 JUXTWKYSGNVPGS-UHFFFAOYSA-N 0.000 description 11
- 108060000200 adenylate cyclase Proteins 0.000 description 11
- 102000030621 adenylate cyclase Human genes 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 10
- 102000007079 Peptide Fragments Human genes 0.000 description 10
- 108010033276 Peptide Fragments Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 208000010125 myocardial infarction Diseases 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 230000003143 atherosclerotic effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000024883 vasodilation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 206010047141 Vasodilatation Diseases 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 5
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 238000000760 immunoelectrophoresis Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000013197 protein A assay Methods 0.000 description 5
- 238000002731 protein assay Methods 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000250 revascularization Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 101150069040 CETP gene Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 101150072832 adcy9 gene Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 4
- 210000000497 foam cell Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000003863 ammonium salts Chemical group 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VHSPKQAESIGBIC-HSZRJFAPSA-N (2r)-3-[3-(4-chloro-3-ethylphenoxy)-n-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(Cl)C(CC)=CC(OC=2C=C(C=CC=2)N(C[C@@H](O)C(F)(F)F)CC=2C=C(OC(F)(F)C(F)F)C=CC=2)=C1 VHSPKQAESIGBIC-HSZRJFAPSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021024 Hypolipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 102000052454 human CETP Human genes 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- WKMYRABSTSFCBR-UHFFFAOYSA-N n-[4-(5-chloro-1,3-benzoxazol-2-yl)phenyl]-2-(2-methylphenoxy)acetamide Chemical compound CC1=CC=CC=C1OCC(=O)NC1=CC=C(C=2OC3=CC=C(Cl)C=C3N=2)C=C1 WKMYRABSTSFCBR-UHFFFAOYSA-N 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FTJPVLBOGWBGON-ISKFKSNPSA-N (2R)-3-[[(3S)-3-(5-chloropyridin-2-yl)-3-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-phenylbutyl]amino]-1,1,1-trifluoropropan-2-ol Chemical compound ClC=1C=CC(=NC=1)[C@](CCNC[C@H](C(F)(F)F)O)(CC1=CC=CC=C1)C1=CC(=CC(=C1)OC(C(F)F)(F)F)F FTJPVLBOGWBGON-ISKFKSNPSA-N 0.000 description 1
- CJGFLSMKDCVJOR-GGAORHGYSA-N (2S)-1,1,1-trifluoro-3-[(2R)-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-2H-quinolin-1-yl]propan-2-ol Chemical compound FC([C@H](CN1[C@H](CCC2=C(C=CC=C12)C1=CC=C(C=C1)OC(F)(F)F)C1=CC(=CC=C1)OC(C(F)F)(F)F)O)(F)F CJGFLSMKDCVJOR-GGAORHGYSA-N 0.000 description 1
- FOKGJUGUCYOLNR-RTWAWAEBSA-N (2S)-1,1,1-trifluoro-3-[(3S)-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazin-4-yl]propan-2-ol Chemical compound FC([C@H](CN1C2=C(OC[C@@H]1C1=CC(=CC=C1)OC(C(F)F)(F)F)C(=CC=C2)C1=CC=C(C=C1)OC(F)(F)F)O)(F)F FOKGJUGUCYOLNR-RTWAWAEBSA-N 0.000 description 1
- PQFCNUNHVJKNCZ-XZOQPEGZSA-N (2r)-3-[(2r)-4-[[3-(difluoromethoxy)phenyl]methyl]-2-[3-(trifluoromethyl)phenyl]-2,3-dihydroquinoxalin-1-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C([C@H](N(C1=CC=CC=C11)C[C@@H](O)C(F)(F)F)C=2C=C(C=CC=2)C(F)(F)F)N1CC1=CC=CC(OC(F)F)=C1 PQFCNUNHVJKNCZ-XZOQPEGZSA-N 0.000 description 1
- WPWXSAZBPXWZGR-GGAORHGYSA-N (2r)-3-[[(2r)-2-(5-chloropyridin-2-yl)-2-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-phenylpropyl]amino]-1,1,1-trifluoropropan-2-ol Chemical compound C([C@](CNC[C@@H](O)C(F)(F)F)(C=1C=C(OC(F)(F)C(F)F)C=C(F)C=1)C=1N=CC(Cl)=CC=1)C1=CC=CC=C1 WPWXSAZBPXWZGR-GGAORHGYSA-N 0.000 description 1
- BTIIJGFMCVLCET-LJQANCHMSA-N (2r)-3-[[4-(4-chloro-3-ethylphenoxy)pyrimidin-2-yl]-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(Cl)C(CC)=CC(OC=2N=C(N=CC=2)N(C[C@@H](O)C(F)(F)F)CC=2C=C(OC(F)(F)C(F)F)C=CC=2)=C1 BTIIJGFMCVLCET-LJQANCHMSA-N 0.000 description 1
- XQVSUCVPHONOCM-YADARESESA-N (3r,9s)-7,7-dimethyl-4-propan-2-yl-3-[4-(trifluoromethyl)phenyl]spiro[3,6,8,9-tetrahydrofuro[3,4-c]quinoline-1,1'-cyclopentane]-9-ol Chemical compound O([C@@H](C1=C2C=3[C@@H](O)CC(C)(C)CC=3N=C1C(C)C)C=1C=CC(=CC=1)C(F)(F)F)C21CCCC1 XQVSUCVPHONOCM-YADARESESA-N 0.000 description 1
- QIDZXVBZLXREST-DEOSSOPVSA-N (4R)-4-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-1,3-oxazolidin-2-one Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1N(C(OC1)=O)CC1=C(C=CC(=C1)C(F)(F)F)C1=C(C=CC(=C1)C(C)C)OC)(F)F QIDZXVBZLXREST-DEOSSOPVSA-N 0.000 description 1
- QIDZXVBZLXREST-XMMPIXPASA-N (4S)-4-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-1,3-oxazolidin-2-one Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@@H]1N(C(OC1)=O)CC1=C(C=CC(=C1)C(F)(F)F)C1=C(C=CC(=C1)C(C)C)OC)(F)F QIDZXVBZLXREST-XMMPIXPASA-N 0.000 description 1
- HDXHZOCAZCLVPB-GBXCKJPGSA-N (4S)-5-(4-fluorophenyl)-6-[(R)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-ol Chemical compound F[C@@H](C=1C(=C2C(=NC=1C(C)C)OC1(C[C@@H]2O)CCC1)C1=CC=C(C=C1)F)C1=CC=C(C=C1)C(F)(F)F HDXHZOCAZCLVPB-GBXCKJPGSA-N 0.000 description 1
- MROSYRHSKOWVBQ-WMZHIEFXSA-N (4S)-5-(4-fluorophenyl)-6-[(R)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclopropane]-4-ol Chemical compound F[C@@H](C=1C(=C2C(=NC=1C(C)C)OC1(C[C@@H]2O)CC1)C1=CC=C(C=C1)F)C1=CC=C(C=C1)C(F)(F)F MROSYRHSKOWVBQ-WMZHIEFXSA-N 0.000 description 1
- HDXHZOCAZCLVPB-RDPSFJRHSA-N (4S)-5-(4-fluorophenyl)-6-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-ol Chemical compound CC(C)C1=NC2=C([C@@H](O)CC3(CCC3)O2)C(C2=CC=C(F)C=C2)=C1[C@@H](F)C1=CC=C(C=C1)C(F)(F)F HDXHZOCAZCLVPB-RDPSFJRHSA-N 0.000 description 1
- MROSYRHSKOWVBQ-CVDCTZTESA-N (4S)-5-(4-fluorophenyl)-6-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclopropane]-4-ol Chemical compound F[C@H](C=1C(=C2C(=NC=1C(C)C)OC1(C[C@@H]2O)CC1)C1=CC=C(C=C1)F)C1=CC=C(C=C1)C(F)(F)F MROSYRHSKOWVBQ-CVDCTZTESA-N 0.000 description 1
- SEKJJJWPBYCAIB-CPJSRVTESA-N (4S)-5-(4-fluorophenyl)-6-[(S)-hydroxy-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-ol Chemical compound CC(C)C1=NC2=C([C@@H](O)CC3(CCC3)O2)C(C2=CC=C(F)C=C2)=C1[C@@H](O)C1=CC=C(C=C1)C(F)(F)F SEKJJJWPBYCAIB-CPJSRVTESA-N 0.000 description 1
- NKYNDWXIWDDBQA-CYFREDJKSA-N (4S)-5-(4-fluorophenyl)-6-[(S)-hydroxy-[4-(trifluoromethyl)phenyl]methyl]-7-propan-2-ylspiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclopropane]-4-ol Chemical compound FC1=CC=C(C=C1)C1=C2C(=NC(=C1[C@H](C1=CC=C(C=C1)C(F)(F)F)O)C(C)C)OC1(C[C@@H]2O)CC1 NKYNDWXIWDDBQA-CYFREDJKSA-N 0.000 description 1
- DFFYRGDTASCAMI-ZJWNCGCPSA-N (4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2,3-dihydroxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC1=C(C=CC(=C1)C(F)(F)F)C1=C(C(=C(C(=C1)C(C)C)F)O)O)C)(F)F DFFYRGDTASCAMI-ZJWNCGCPSA-N 0.000 description 1
- ITZTZHDJEGKKKT-LMMUFQDNSA-N (4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)cyclohexen-1-yl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC1=C(CCC(C1)C(F)(F)F)C1=C(C=C(C(=C1)C(C)C)F)OC)C)(F)F ITZTZHDJEGKKKT-LMMUFQDNSA-N 0.000 description 1
- NGXFUDJYAKOSFK-FNODVLLQSA-N (4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-[4-fluoro-2,3-dihydroxy-5-(2-hydroxypropan-2-yl)phenyl]-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC1=C(C=CC(=C1)C(F)(F)F)C1=C(C(=C(C(=C1)C(C)(C)O)F)O)O)C)(F)F NGXFUDJYAKOSFK-FNODVLLQSA-N 0.000 description 1
- ZLMDMGVNLQHTAU-DXPJPUQTSA-N (4r,5r)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@H]1C ZLMDMGVNLQHTAU-DXPJPUQTSA-N 0.000 description 1
- ZLMDMGVNLQHTAU-AKJBCIBTSA-N (4r,5s)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@H]1C ZLMDMGVNLQHTAU-AKJBCIBTSA-N 0.000 description 1
- ZLMDMGVNLQHTAU-QMTYFTJSSA-N (4s,5r)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C ZLMDMGVNLQHTAU-QMTYFTJSSA-N 0.000 description 1
- ZLMDMGVNLQHTAU-YHAMSUFESA-N (4s,5s)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C ZLMDMGVNLQHTAU-YHAMSUFESA-N 0.000 description 1
- XYMCQCXEGYUQJU-HWRSSNJWSA-N (4s,5s)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-hydroxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound C1=C(F)C(C(C)C)=CC(C=2C(=CC(=CC=2)C(F)(F)F)CN2C(O[C@H]([C@@H]2C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=O)=C1O XYMCQCXEGYUQJU-HWRSSNJWSA-N 0.000 description 1
- IPYXWSIBCVUPBE-HOFKKMOUSA-N (5s)-2-cyclopentyl-4-(4-fluorophenyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C=2C=CC(F)=CC=2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C1CCCC1 IPYXWSIBCVUPBE-HOFKKMOUSA-N 0.000 description 1
- XVUDQBUEUFZZQH-ZQAZVOLISA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(3-hydroxy-3-methylbutoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCCC(C)(O)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XVUDQBUEUFZZQH-ZQAZVOLISA-N 0.000 description 1
- WJOGSZFWTRQDJL-ZJJOJAIXSA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(1-methylpiperidin-4-yl)oxypyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1CN(C)CCC1OC1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 WJOGSZFWTRQDJL-ZJJOJAIXSA-N 0.000 description 1
- HNPNOKPKJPAVPV-NVQXNPDNSA-N (5s)-4-(4-fluorophenyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-propan-2-ylspiro[6,8-dihydro-5h-quinoline-7,1'-cyclobutane]-5-ol Chemical compound C=1([C@@H](O)C2)C(C=3C=CC(F)=CC=3)=C([C@@H](F)C=3C=CC(=CC=3)C(F)(F)F)C(C(C)C)=NC=1CC12CCC1 HNPNOKPKJPAVPV-NVQXNPDNSA-N 0.000 description 1
- STYMPUZEPCZPEZ-FIPFOOKPSA-N (5s)-4-cyclohexyl-2-cyclopentyl-3-[(s)-hydroxy-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](O)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCCCC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C1CCCC1 STYMPUZEPCZPEZ-FIPFOOKPSA-N 0.000 description 1
- BBGDZXUCEYOTHB-VWLOTQADSA-N (5s)-4-cyclohexyl-2-cyclopentyl-7,7-dimethyl-3-[[4-(trifluoromethyl)phenyl]methyl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC1=C(C2CCCCC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C1CCCC1 BBGDZXUCEYOTHB-VWLOTQADSA-N 0.000 description 1
- DCGKVWUPMGGBHY-SANMLTNESA-N (5s)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4,4-dimethyl-1,3-oxazolidin-2-one Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(C)(C)[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)OC1=O DCGKVWUPMGGBHY-SANMLTNESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GUUGXBLNGYDANT-UHFFFAOYSA-N 1,1,1-trifluoro-3-[2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-2h-quinolin-1-yl]propan-2-ol Chemical compound FC(F)(F)C(O)CN1C(C=2C=C(OC(F)(F)C(F)F)C=CC=2)CCC2=C1C=CC=C2C1=CC=CC(OC(F)(F)F)=C1 GUUGXBLNGYDANT-UHFFFAOYSA-N 0.000 description 1
- MOOACFAVSYOZPW-UHFFFAOYSA-N 1,1,1-trifluoro-3-[3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazin-4-yl]propan-2-ol Chemical compound FC(F)(F)C(O)CN1C(C=2C=C(OC(F)(F)C(F)F)C=CC=2)COC2=C1C=CC=C2C1=CC=CC(OC(F)(F)F)=C1 MOOACFAVSYOZPW-UHFFFAOYSA-N 0.000 description 1
- XNYMOOHZPFZFJE-UHFFFAOYSA-N 1,1,1-trifluoro-3-[3-phenoxy-n-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]propan-2-ol Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1N(CC(O)C(F)(F)F)CC1=CC=CC(OC(F)(F)C(F)F)=C1 XNYMOOHZPFZFJE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CWPDDPRIKADOKV-QFIPXVFZSA-N 1-[(1s)-1-(5-chloropyridin-2-yl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-(2,2,2-trifluoroethyl)urea Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)NCC(F)(F)F)C=2N=CC(Cl)=CC=2)=C1 CWPDDPRIKADOKV-QFIPXVFZSA-N 0.000 description 1
- JKPLEZZMLLSVDS-VWLOTQADSA-N 1-[(1s)-1-(5-chloropyridin-2-yl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-(3,3-difluorocyclobutyl)urea Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)NC2CC(F)(F)C2)C=2N=CC(Cl)=CC=2)=C1 JKPLEZZMLLSVDS-VWLOTQADSA-N 0.000 description 1
- AMAKXBAXHDIALG-IBVKSMDESA-N 1-[(1s)-1-(5-chloropyridin-2-yl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-[(1r)-3,3-difluorocyclopentyl]urea Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)N[C@H]2CC(F)(F)CC2)C=2N=CC(Cl)=CC=2)=C1 AMAKXBAXHDIALG-IBVKSMDESA-N 0.000 description 1
- DLEGYAJVPJEXJD-SANMLTNESA-N 1-[(1s)-1-(5-chloropyridin-2-yl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-cyclopentylurea Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)NC2CCCC2)C=2N=CC(Cl)=CC=2)=C1 DLEGYAJVPJEXJD-SANMLTNESA-N 0.000 description 1
- RCAOFIWUQXKBOC-UHFFFAOYSA-N 1-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[[2-[ethyl(2-methoxyethyl)amino]phenyl]methyl]amino]pyrimidin-5-yl]piperidine-4-carboxylic acid Chemical compound FC(C=1C=C(CN(C2=NC=C(C=N2)N2CCC(CC2)C(=O)O)CC2=C(C=CC=C2)N(CCOC)CC)C=C(C=1)C(F)(F)F)(F)F RCAOFIWUQXKBOC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GHMCGHQFJNXGCH-UHFFFAOYSA-N 2-(4-chloro-2,3-dimethylphenoxy)-n-[4-(5-cyano-1,3-benzoxazol-2-yl)phenyl]acetamide Chemical compound CC1=C(Cl)C=CC(OCC(=O)NC=2C=CC(=CC=2)C=2OC3=CC=C(C=C3N=2)C#N)=C1C GHMCGHQFJNXGCH-UHFFFAOYSA-N 0.000 description 1
- FOQSJNKVUNMJIP-UHFFFAOYSA-N 2-[4-[2-[3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy]ethylamino]phenyl]-1,3-benzoxazole-5-carbonitrile Chemical compound FC(C(COCCNC1=CC=C(C=C1)C=1OC2=C(N=1)C=C(C=C2)C#N)(C(F)(F)F)C)(F)F FOQSJNKVUNMJIP-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phospho-D-glyceric acid Chemical compound OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 1
- GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical class OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 description 1
- CKWPFZGLEDHAMO-UHFFFAOYSA-N 3,5-dichloro-n-[2-(4-chlorophenyl)ethyl]-n-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]methyl]benzamide Chemical compound C1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1CN(C(=O)C=1C=C(Cl)C=C(Cl)C=1)CCC1=CC=C(Cl)C=C1 CKWPFZGLEDHAMO-UHFFFAOYSA-N 0.000 description 1
- FVKYVDYSLDNIGH-QWXGXRTQSA-N 3-[3-[2-[[(4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-6-methoxypyridin-3-yl]-4-methoxyphenyl]propanoic acid Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC1=NC(=CC=C1C=1C=C(C=CC=1OC)CCC(=O)O)OC)C)(F)F FVKYVDYSLDNIGH-QWXGXRTQSA-N 0.000 description 1
- GMKAMQSQOBJYPN-XRHLQHRESA-N 3-[4-[2-[[(4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-4,4-dimethylcyclohexen-1-yl]-3-methoxyphenyl]-2,2-dimethylpropanoic acid Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC=1CC(CCC=1C1=C(C=C(C=C1)CC(C(=O)O)(C)C)OC)(C)C)C)(F)F GMKAMQSQOBJYPN-XRHLQHRESA-N 0.000 description 1
- KCELZBJBUMZXEK-UHFFFAOYSA-N 3-[5-(4-chloro-3-ethylphenoxy)-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-3,4-dihydro-2h-quinolin-1-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(Cl)C(CC)=CC(OC=2C=3CCC(N(CC(O)C(F)(F)F)C=3C=CC=2)C=2C=C(OC(F)(F)C(F)F)C=CC=2)=C1 KCELZBJBUMZXEK-UHFFFAOYSA-N 0.000 description 1
- QIYSEONIDZRUEG-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-5-bromo-n-(cyclopentylmethyl)-n-ethyl-6-methylpyridin-2-amine Chemical compound N=1C(C)=C(Br)C=C(CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)C=1N(CC)CC1CCCC1 QIYSEONIDZRUEG-UHFFFAOYSA-N 0.000 description 1
- FFQWXRNSFLKISH-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N-(cyclopentylmethyl)-N-ethyl-6-methyl-5-methylsulfanylpyridin-2-amine Chemical compound FC(C=1C=C(CN(C=2N=NN(N=2)C)CC=2C(=NC(=C(C=2)SC)C)N(CC)CC2CCCC2)C=C(C=1)C(F)(F)F)(F)F FFQWXRNSFLKISH-UHFFFAOYSA-N 0.000 description 1
- FPTZHWFBRGUFAQ-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-morpholin-4-ylpyrimidin-2-yl)amino]methyl]-n,n-bis(cyclopropylmethyl)-7,7-dimethyl-5,6-dihydrocyclopenta[b]pyridin-2-amine Chemical compound C1CC1CN(CC1CC1)C=1N=C2C(C)(C)CCC2=CC=1CN(C=1N=CC(=CN=1)N1CCOCC1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FPTZHWFBRGUFAQ-UHFFFAOYSA-N 0.000 description 1
- DLVFSTDPHRLXSF-UHFFFAOYSA-N 3-[[[3-[cyclopentylmethyl(ethyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-5-(trifluoromethyl)benzonitrile Chemical compound C=1C=2CCCCC=2C=C(CN(CC=2C=C(C=C(C=2)C#N)C(F)(F)F)C2=NN(C)N=N2)C=1N(CC)CC1CCCC1 DLVFSTDPHRLXSF-UHFFFAOYSA-N 0.000 description 1
- BJHMTYWHFLWIGR-UHFFFAOYSA-N 3-[[[3-[cyclopentylmethyl(ethyl)amino]-6-methoxypyridin-2-yl]methyl-[5-(2-methylsulfonylethoxy)pyrimidin-2-yl]amino]methyl]-5-(trifluoromethyl)benzonitrile Chemical compound C=1C=C(OC)N=C(CN(CC=2C=C(C=C(C=2)C#N)C(F)(F)F)C=2N=CC(OCCS(C)(=O)=O)=CN=2)C=1N(CC)CC1CCCC1 BJHMTYWHFLWIGR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HZGRSKASCNYHDQ-UHFFFAOYSA-N 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)-n-[[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]benzamide Chemical compound O1C=2C(C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1C(=O)NCC(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 HZGRSKASCNYHDQ-UHFFFAOYSA-N 0.000 description 1
- HZUXXUXWTGSYIO-UHFFFAOYSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-N-[[1-[5-(5-fluoro-2-propan-2-ylphenyl)pyridin-2-yl]piperidin-4-yl]methyl]benzamide Chemical compound C(#N)C=1C=C(C2=C(N=C(O2)C2=CC=C(C(=O)NCC3CCN(CC3)C3=NC=C(C=C3)C3=C(C=CC(=C3)F)C(C)C)C=C2)C=1)C(C)C HZUXXUXWTGSYIO-UHFFFAOYSA-N 0.000 description 1
- OWGKJJXRTGKLIN-UHFFFAOYSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-N-[[1-[5-(5-methyl-2-propan-2-ylphenyl)pyridin-2-yl]piperidin-4-yl]methyl]benzamide Chemical compound C(#N)C=1C=C(C2=C(N=C(O2)C2=CC=C(C(=O)NCC3CCN(CC3)C3=NC=C(C=C3)C3=C(C=CC(=C3)C)C(C)C)C=C2)C=1)C(C)C OWGKJJXRTGKLIN-UHFFFAOYSA-N 0.000 description 1
- VIKKXFYHSNSWKV-XMMPIXPASA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-n-[[(5r)-2-oxo-3-[5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl]-1,3-oxazolidin-5-yl]methyl]benzamide Chemical compound C([C@H](OC1=O)CNC(=O)C2=CC=C(C=C2)C2=NC=3C=C(C=C(C=3O2)C(C)C)C#N)N1C(N=C1)=CC=C1C1=CC=CC=C1OC(F)(F)F VIKKXFYHSNSWKV-XMMPIXPASA-N 0.000 description 1
- UGWNBYVDMSHMDF-UUWRZZSWSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-n-[[(5r)-5-methyl-2-oxo-3-[5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl]-1,3-oxazolidin-5-yl]methyl]benzamide Chemical compound C([C@@](OC1=O)(C)CNC(=O)C2=CC=C(C=C2)C2=NC=3C=C(C=C(C=3O2)C(C)C)C#N)N1C(N=C1)=CC=C1C1=CC=CC=C1OC(F)(F)F UGWNBYVDMSHMDF-UUWRZZSWSA-N 0.000 description 1
- VIKKXFYHSNSWKV-DEOSSOPVSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-n-[[(5s)-2-oxo-3-[5-[2-(trifluoromethoxy)phenyl]pyridin-2-yl]-1,3-oxazolidin-5-yl]methyl]benzamide Chemical compound C([C@@H](OC1=O)CNC(=O)C2=CC=C(C=C2)C2=NC=3C=C(C=C(C=3O2)C(C)C)C#N)N1C(N=C1)=CC=C1C1=CC=CC=C1OC(F)(F)F VIKKXFYHSNSWKV-DEOSSOPVSA-N 0.000 description 1
- MZNTVTSBOKBKLG-UHFFFAOYSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-n-[[1-(5-phenylpyridin-2-yl)piperidin-4-yl]methyl]benzamide Chemical compound O1C=2C(C(C)C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1C(=O)NCC(CC1)CCN1C(N=C1)=CC=C1C1=CC=CC=C1 MZNTVTSBOKBKLG-UHFFFAOYSA-N 0.000 description 1
- KOKOEENWFVYHLA-UHFFFAOYSA-N 4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)-n-[[1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl]methyl]benzamide Chemical compound O1C=2C(C(C)C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1C(=O)NCC(CC1)CCN1C1=CC=C(C(F)(F)F)C=N1 KOKOEENWFVYHLA-UHFFFAOYSA-N 0.000 description 1
- SQMPIEVBIWMFLS-UHFFFAOYSA-N 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[[3-[cyclopropylmethyl(propyl)amino]quinolin-2-yl]methyl]amino]pyrimidin-5-yl]oxybutanoic acid Chemical compound FC(C=1C=C(CN(C2=NC=C(C=N2)OCCCC(=O)O)CC2=NC3=CC=CC=C3C=C2N(CCC)CC2CC2)C=C(C=1)C(F)(F)F)(F)F SQMPIEVBIWMFLS-UHFFFAOYSA-N 0.000 description 1
- QIDZXVBZLXREST-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)OCC1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QIDZXVBZLXREST-UHFFFAOYSA-N 0.000 description 1
- QEUHYNKIPZXTFD-QPHCHLROSA-N 4-[3-[6-(azetidin-1-yl)-2-[[(4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]pyridin-3-yl]-5-fluoro-4-methoxyphenyl]-3-methylbenzoic acid Chemical compound N1(CCC1)C1=CC=C(C(=N1)CN1C(O[C@H]([C@@H]1C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O)C=1C=C(C=C(C=1OC)F)C1=C(C=C(C=C1)C(=O)O)C QEUHYNKIPZXTFD-QPHCHLROSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QXLKXWSIEGNMEN-UHFFFAOYSA-N 5-[2,6-bis(trifluoromethyl)pyridin-4-yl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)OC(C=2C=C(N=C(C=2)C(F)(F)F)C(F)(F)F)C1C QXLKXWSIEGNMEN-UHFFFAOYSA-N 0.000 description 1
- FGNMVXHMLIFOIL-UHFFFAOYSA-N 5-[[1-[3,5-bis(trifluoromethyl)phenyl]ethyl-[5-(2-methylsulfonylethoxy)pyrimidin-2-yl]amino]methyl]-N-(cyclopentylmethyl)-N-ethyl-1,3-dimethylindazol-6-amine Chemical compound CCN(CC1CCCC1)c1cc2n(C)nc(C)c2cc1CN(C(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1ncc(OCCS(C)(=O)=O)cn1 FGNMVXHMLIFOIL-UHFFFAOYSA-N 0.000 description 1
- PPKJVIUMTWMSRG-UHFFFAOYSA-N 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-n-(cyclopentylmethyl)-n-ethyl-1,3-dimethylpyrazolo[3,4-b]pyridin-6-amine Chemical compound N=1C=2N(C)N=C(C)C=2C=C(CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)C=1N(CC)CC1CCCC1 PPKJVIUMTWMSRG-UHFFFAOYSA-N 0.000 description 1
- ABLZFNXTOHCXHX-UHFFFAOYSA-N 5-chloro-6-fluoro-n-[2-[3-(trifluoromethoxy)phenyl]ethyl]-n-[(4-trimethylsilylphenyl)methyl]-1h-indole-7-carboxamide Chemical compound C1=CC([Si](C)(C)C)=CC=C1CN(C(=O)C=1C=2NC=CC=2C=C(Cl)C=1F)CCC1=CC=CC(OC(F)(F)F)=C1 ABLZFNXTOHCXHX-UHFFFAOYSA-N 0.000 description 1
- GBRGKUGFCDNULU-UHFFFAOYSA-N 5-chloro-6-fluoro-n-[2-[3-(trifluoromethyl)phenyl]ethyl]-n-[(4-trimethylsilylphenyl)methyl]-1h-indole-7-carboxamide Chemical compound C1=CC([Si](C)(C)C)=CC=C1CN(C(=O)C=1C=2NC=CC=2C=C(Cl)C=1F)CCC1=CC=CC(C(F)(F)F)=C1 GBRGKUGFCDNULU-UHFFFAOYSA-N 0.000 description 1
- GZHXEBSHPZKQQD-UHFFFAOYSA-N 6-[[2-[bis(cyclopropylmethyl)amino]-7,7-dimethyl-5,6-dihydrocyclopenta[b]pyridin-3-yl]methyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3h-1,3-benzoxazol-2-one Chemical compound C1CC1CN(CC1CC1)C=1N=C2C(C)(C)CCC2=CC=1CN(C=1C=C2OC(=O)NC2=CC=1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GZHXEBSHPZKQQD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 101710126338 Apamin Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- HKASDKLLEVWKJA-YADARESESA-N BI-5756 Chemical compound O([C@@H](C1=C2C=3[C@@H](O)CC(C)(C)CC=3N=C1C(C)C)C=1C=CC(=CC=1)C(F)(F)F)C21CCOCC1 HKASDKLLEVWKJA-YADARESESA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WDDUXEUDMPMIPG-VWMXVWASSA-N C12([C@@H](O)C=3N=C(C4=C(C5(CCOCC5)O[C@@H]4C=4C=CC(=CC=4)C(F)(F)F)C=3[C@@H](O)C1)C(C)C)CC2 Chemical compound C12([C@@H](O)C=3N=C(C4=C(C5(CCOCC5)O[C@@H]4C=4C=CC(=CC=4)C(F)(F)F)C=3[C@@H](O)C1)C(C)C)CC2 WDDUXEUDMPMIPG-VWMXVWASSA-N 0.000 description 1
- MSYCBVIYZPGQJO-UHFFFAOYSA-N CC(C)C1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C)C1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O MSYCBVIYZPGQJO-UHFFFAOYSA-N 0.000 description 1
- NWOCAGQGDHBXEQ-UHFFFAOYSA-N CC(C)CCC1(CCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C)CCC1(CCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O NWOCAGQGDHBXEQ-UHFFFAOYSA-N 0.000 description 1
- HGUCCYNTDMPKQZ-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O HGUCCYNTDMPKQZ-UHFFFAOYSA-N 0.000 description 1
- INRJMGDKQSJDAE-UHFFFAOYSA-N CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(F)=C1F)=O Chemical compound CC(C)CCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(F)=C1F)=O INRJMGDKQSJDAE-UHFFFAOYSA-N 0.000 description 1
- HQPQEKGKTJROJN-UHFFFAOYSA-N CCCCCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O Chemical compound CCCCCC1(CCCCC1)C(NC(C([S+]=C(C(C)(C)C)[O-])=C1)=CC(Cl)=C1Cl)=O HQPQEKGKTJROJN-UHFFFAOYSA-N 0.000 description 1
- KGWDOBNQDXDZTI-MJGOQNOKSA-N CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)c2nnn(C)n2)c2nc(OC)ccc12 Chemical compound CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)c2nnn(C)n2)c2nc(OC)ccc12 KGWDOBNQDXDZTI-MJGOQNOKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108700012841 Cholesteryl Ester Transfer Protein Deficiency Proteins 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IHIUGIVXARLYHP-UXNJHFGPSA-N Evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2CC1CCC(C(O)=O)CC1 IHIUGIVXARLYHP-UXNJHFGPSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 1
- 101100135848 Mus musculus Pcsk9 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- VHVGQTQWTDTENQ-JGCGQSQUSA-N N-[(1R)-1-(3-cyclopropyloxy-4-fluorophenyl)-1-[3-fluoro-5-(2,2,3,3-tetrafluoropropanoyl)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide Chemical compound C1(CC1)OC=1C=C(C=CC=1F)[C@](CC1=CC=CC=C1)(C1=CC(=CC(=C1)C(C(C(F)F)(F)F)=O)F)NC(C1=CC(=C(C=C1)F)C(F)(F)F)=O VHVGQTQWTDTENQ-JGCGQSQUSA-N 0.000 description 1
- YTIDRXHFQQMFPW-UHFFFAOYSA-N N-[(5-tert-butylthiophen-2-yl)methyl]-5-chloro-2-(methylamino)-N-[2-[4-(trifluoromethyl)phenyl]ethyl]pyridine-3-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(S1)CN(C(C1=C(N=CC(=C1)Cl)NC)=O)CCC1=CC=C(C=C1)C(F)(F)F YTIDRXHFQQMFPW-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NLCQBRJQDXHDEL-CBZJRKILSA-N N-[4-[2-[[(4S,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-4,4-dimethylcyclohexen-1-yl]-3-methoxyphenyl]-N-methylacetamide Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)[C@H]1[C@@H](N(C(O1)=O)CC=1CC(CCC=1C1=C(C=C(C=C1)N(C(C)=O)C)OC)(C)C)C)(F)F NLCQBRJQDXHDEL-CBZJRKILSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- KBFUQFVFYYBHBT-UHFFFAOYSA-N TRAM-34 Chemical compound ClC1=CC=CC=C1C(N1N=CC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 KBFUQFVFYYBHBT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IPHVISNFTJFEIE-FQEVSTJZSA-N [(5s)-2-cyclopentyl-4-ethyl-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-3-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@H](O)C1=C(C=2C(=O)C=3C=CC(=CC=3)C(F)(F)F)CC)C(C)(C)CC1=NC=2C1CCCC1 IPHVISNFTJFEIE-FQEVSTJZSA-N 0.000 description 1
- SNJLJLHEGUOVAN-NRFANRHFSA-N [(5s)-2-cyclopentyl-5-hydroxy-4-propan-2-ylspiro[6,8-dihydro-5h-quinoline-7,1'-cyclobutane]-3-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@H](O)C1=C(C(=C(C2CCCC2)N=C1C1)C(=O)C=2C=CC(=CC=2)C(F)(F)F)C(C)C)C21CCC2 SNJLJLHEGUOVAN-NRFANRHFSA-N 0.000 description 1
- BQJMQLJEPFRFFT-FQEVSTJZSA-N [(5s)-2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-propan-2-yl-6,8-dihydro-5h-quinolin-3-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@H](O)C1=C(C=2C(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C)C)C(C)(C)CC1=NC=2C1CCCC1 BQJMQLJEPFRFFT-FQEVSTJZSA-N 0.000 description 1
- QJKLVVVZLDQNKF-QFIPXVFZSA-N [(5s)-4-cyclohexyl-5-hydroxy-2-propan-2-ylspiro[6,8-dihydro-5h-quinoline-7,1'-cyclobutane]-3-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C=1([C@@H](O)C2)C(C3CCCCC3)=C(C(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C(C)C)=NC=1CC12CCC1 QJKLVVVZLDQNKF-QFIPXVFZSA-N 0.000 description 1
- JKTJFUOSZGUZHL-NRFANRHFSA-N [(5s)-4-cyclohexyl-5-hydroxy-7,7-dimethyl-2-propan-2-yl-6,8-dihydro-5h-quinolin-3-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C=1([C@@H](O)CC(C)(C)CC=1N=C(C=1C(=O)C=2C=CC(=CC=2)C(F)(F)F)C(C)C)C=1C1CCCCC1 JKTJFUOSZGUZHL-NRFANRHFSA-N 0.000 description 1
- NOHRUKAGQHKAAG-UHFFFAOYSA-N [2-phenyl-1-pyridin-2-yl-1-[3-(trifluoromethyl)phenyl]ethyl] 3,3-dimethylbutanoate Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C=1N=CC=CC=1)(OC(=O)CC(C)(C)C)CC1=CC=CC=C1 NOHRUKAGQHKAAG-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VFRROHXSMXFLSN-SLPGGIOYSA-N aldehydo-D-glucose 6-phosphate Chemical class OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-SLPGGIOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 150000001661 cadmium Chemical class 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CLRKALOZGYAVSK-CTNGQTDRSA-N ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-8-methyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound FC(C=1C=C(CN([C@H]2C[C@H](N(C3=C(C=C(C=C23)C(F)(F)F)C)C(=O)OCC)CC)C=2N=NN(N=2)C)C=C(C=1)C(F)(F)F)(F)F CLRKALOZGYAVSK-CTNGQTDRSA-N 0.000 description 1
- HUEQGWQYCQDCRR-QUCCMNQESA-N ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-6-(dimethylamino)-2-ethyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate Chemical compound FC(C=1C=C(CN([C@H]2C[C@H](N(C3=CC=C(N=C23)N(C)C)C(=O)OCC)CC)C=2N=NN(N=2)C)C=C(C=1)C(F)(F)F)(F)F HUEQGWQYCQDCRR-QUCCMNQESA-N 0.000 description 1
- JDYYBIBWKOPTOR-RDGATRHJSA-N ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-morpholin-4-ylpyrimidin-2-yl)amino]-2-ethyl-6-methoxy-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate Chemical compound FC(C=1C=C(CN([C@H]2C[C@H](N(C3=CC=C(N=C23)OC)C(=O)OCC)CC)C2=NC=C(C=N2)N2CCOCC2)C=C(C=1)C(F)(F)F)(F)F JDYYBIBWKOPTOR-RDGATRHJSA-N 0.000 description 1
- IMRVLDZUBNUSFG-MJGOQNOKSA-N ethyl (2R,4S)-4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate Chemical compound FC(C=1C=C(CN(C(C)=O)[C@H]2C[C@H](N(C3=CC=C(N=C23)C(F)(F)F)C(=O)OCC)CC)C=C(C=1)C(F)(F)F)(F)F IMRVLDZUBNUSFG-MJGOQNOKSA-N 0.000 description 1
- YIOZRSMRZYROOY-QUCCMNQESA-N ethyl (2R,4S)-4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-methoxy-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate Chemical compound FC(C=1C=C(CN(C(C)=O)[C@H]2C[C@H](N(C3=CC=C(N=C23)OC)C(=O)OCC)CC)C=C(C=1)C(F)(F)F)(F)F YIOZRSMRZYROOY-QUCCMNQESA-N 0.000 description 1
- TYSVVPABTRPKEA-CTNGQTDRSA-N ethyl (2R,4S)-4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-(dimethylamino)-2-ethyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate Chemical compound FC(C=1C=C(CN(C(C)=O)[C@H]2C[C@H](N(C3=CC=C(N=C23)N(C)C)C(=O)OCC)CC)C=C(C=1)C(F)(F)F)(F)F TYSVVPABTRPKEA-CTNGQTDRSA-N 0.000 description 1
- UTZUWWOYAALDNK-QUCCMNQESA-N ethyl (2r,4s)-4-[2-[3,5-bis(trifluoromethyl)phenyl]ethoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)C(=O)OCCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UTZUWWOYAALDNK-QUCCMNQESA-N 0.000 description 1
- HKIYBPBTPLEQTN-AEFFLSMTSA-N ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-1,5-naphthyridine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@@H](CC)N(C2=CC=C(N=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HKIYBPBTPLEQTN-AEFFLSMTSA-N 0.000 description 1
- MJCYPWYWAVUFGD-NQIIRXRSSA-N ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MJCYPWYWAVUFGD-NQIIRXRSSA-N 0.000 description 1
- XZGVDRYUFWHBPH-KCWPFWIISA-N ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-morpholin-4-ylpyrimidin-2-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N=1C=C(N2CCOCC2)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XZGVDRYUFWHBPH-KCWPFWIISA-N 0.000 description 1
- HEKSBRDADHIRFB-QPPBQGQZSA-N ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[5-(2-methylsulfonylethoxy)pyrimidin-2-yl]amino]-2-ethyl-6-methoxy-3,4-dihydro-2h-1,5-naphthyridine-1-carboxylate Chemical compound N=1C=C(OCCS(C)(=O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(OC)N=C21)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HEKSBRDADHIRFB-QPPBQGQZSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- NCENLFSUCGXOGV-UHFFFAOYSA-N methyl N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[[2-(2-oxo-1,3-oxazolidin-3-yl)-5-(trifluoromethyl)phenyl]methyl]carbamate Chemical compound FC(C=1C=C(CN(C(OC)=O)CC2=C(C=CC(=C2)C(F)(F)F)N2C(OCC2)=O)C=C(C=1)C(F)(F)F)(F)F NCENLFSUCGXOGV-UHFFFAOYSA-N 0.000 description 1
- GKGFYDKPZCFALY-UHFFFAOYSA-N methyl N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[[2-(2-oxoimidazolidin-1-yl)-5-(trifluoromethyl)phenyl]methyl]carbamate Chemical compound FC(C=1C=C(CN(C(OC)=O)CC2=C(C=CC(=C2)C(F)(F)F)N2C(NCC2)=O)C=C(C=1)C(F)(F)F)(F)F GKGFYDKPZCFALY-UHFFFAOYSA-N 0.000 description 1
- WJFLAPADUXOLSJ-UHFFFAOYSA-N methyl N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[[2-[ethoxycarbonyl(propyl)amino]-5-(trifluoromethyl)phenyl]methyl]carbamate Chemical compound FC(C=1C=C(CN(C(OC)=O)CC2=C(C=CC(=C2)C(F)(F)F)N(CCC)C(=O)OCC)C=C(C=1)C(F)(F)F)(F)F WJFLAPADUXOLSJ-UHFFFAOYSA-N 0.000 description 1
- FLZUSMRJISRMKG-UHFFFAOYSA-N methyl n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]carbamate Chemical compound C=1C(C(F)(F)F)=CC=C(C=2C(=CC=C(C=2)C(C)C)OC)C=1CN(C(=O)OC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FLZUSMRJISRMKG-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- CHLOYGDBHBRFNK-MHZLTWQESA-N n-[(1s)-1-(5-chloropyridin-2-yl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide Chemical compound FC(F)C(F)(F)OC1=CC(F)=CC([C@](CC=2C=CC=CC=2)(NC(=O)C=2C=C(C(F)=CC=2)C(F)(F)F)C=2N=CC(Cl)=CC=2)=C1 CHLOYGDBHBRFNK-MHZLTWQESA-N 0.000 description 1
- MVDQGGQMPIIVJN-UHFFFAOYSA-N n-[(4-tert-butylphenyl)methyl]-5-chloro-n-[2-[3-(trifluoromethyl)phenyl]ethyl]-1h-pyrrolo[2,3-c]pyridine-7-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1CN(C(=O)C=1C=2NC=CC=2C=C(Cl)N=1)CCC1=CC=CC(C(F)(F)F)=C1 MVDQGGQMPIIVJN-UHFFFAOYSA-N 0.000 description 1
- IPEQHQPRCFXTGK-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-n-[[2-[cyclopentylmethyl(ethyl)amino]-5-(trifluoromethyl)phenyl]methyl]-5-(2-methylsulfonylethoxy)pyrimidin-2-amine Chemical compound C=1C=C(C(F)(F)F)C=C(CN(C(C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2N=CC(OCCS(C)(=O)=O)=CN=2)C=1N(CC)CC1CCCC1 IPEQHQPRCFXTGK-UHFFFAOYSA-N 0.000 description 1
- UPOZHEPYKTXDHX-UHFFFAOYSA-N n-[4-(5,7-dimethyl-1,3-benzoxazol-2-yl)phenyl]-2-(2-methylphenoxy)acetamide Chemical compound N=1C2=CC(C)=CC(C)=C2OC=1C(C=C1)=CC=C1NC(=O)COC1=CC=CC=C1C UPOZHEPYKTXDHX-UHFFFAOYSA-N 0.000 description 1
- JJEWIXRNUSUVRS-UHFFFAOYSA-N n-[4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(2-methylphenoxy)acetamide Chemical compound CC1=CC=CC=C1OCC(=O)NC1=CC=C(C=2OC3=C(C)C=C(C=C3N=2)C#N)C=C1 JJEWIXRNUSUVRS-UHFFFAOYSA-N 0.000 description 1
- TWXKMLUDQFBGTJ-UHFFFAOYSA-N n-[4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)phenyl]-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetamide Chemical compound O1C=2C(C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1NC(=O)CN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 TWXKMLUDQFBGTJ-UHFFFAOYSA-N 0.000 description 1
- IUDTVCXGFXDRDM-UHFFFAOYSA-N n-[4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)phenyl]-2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]acetamide Chemical compound O1C=2C(C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1NC(=O)CN(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 IUDTVCXGFXDRDM-UHFFFAOYSA-N 0.000 description 1
- WXYZREDHIRRZOA-UHFFFAOYSA-N n-[4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)phenyl]-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]acetamide Chemical compound O1C=2C(C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1NC(=O)CN(CC1)CCN1C1=CC=C(C(F)(F)F)C=N1 WXYZREDHIRRZOA-UHFFFAOYSA-N 0.000 description 1
- DPSYAEWABAXSIW-UHFFFAOYSA-N n-[4-[5-cyano-7-(2-hydroxypropan-2-yl)-1,3-benzoxazol-2-yl]phenyl]-2-(2-methylphenoxy)acetamide Chemical compound CC1=CC=CC=C1OCC(=O)NC1=CC=C(C=2OC3=C(C=C(C=C3N=2)C#N)C(C)(C)O)C=C1 DPSYAEWABAXSIW-UHFFFAOYSA-N 0.000 description 1
- KFIQMXGFKZZXAY-UHFFFAOYSA-N n-[[4-(4-tert-butylphenyl)cyclohexyl]methyl]-4-(5-cyano-7-propan-2-yl-1,3-benzoxazol-2-yl)benzamide Chemical compound O1C=2C(C(C)C)=CC(C#N)=CC=2N=C1C(C=C1)=CC=C1C(=O)NCC(CC1)CCC1C1=CC=C(C(C)(C)C)C=C1 KFIQMXGFKZZXAY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HEMJMIZAXNWBAM-WTQRLHSKSA-N propan-2-yl (2R)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[5-(1-methylpyrazol-4-yl)pyrimidin-2-yl]amino]-2-ethylpyrrolidine-1-carboxylate Chemical compound FC(C=1C=C(CN(C2C[C@H](N(C2)C(=O)OC(C)C)CC)C2=NC=C(C=N2)C=2C=NN(C=2)C)C=C(C=1)C(F)(F)F)(F)F HEMJMIZAXNWBAM-WTQRLHSKSA-N 0.000 description 1
- QOTNDQXNQFOMCL-CTDNXKOOSA-N propan-2-yl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxypropyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound FC(C=1C=C(CN([C@H]2C[C@H](N(C3=CC=C(C=C23)C(F)(F)F)C(=O)OC(C)C)CC)C=2N=NN(N=2)CC(C)O)C=C(C=1)C(F)(F)F)(F)F QOTNDQXNQFOMCL-CTDNXKOOSA-N 0.000 description 1
- URHFSMKLJVQQMJ-CTNGQTDRSA-N propan-2-yl (2r,4s)-4-[(3,5-dichlorophenyl)methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-methyl-3,4-dihydro-2h-1,5-naphthyridine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C)N=C21)C(=O)OC(C)C)CC)CC1=CC(Cl)=CC(Cl)=C1 URHFSMKLJVQQMJ-CTNGQTDRSA-N 0.000 description 1
- VKCTUQWVWVLYST-OFNKIYASSA-N propan-2-yl (2r,4s)-4-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CCN)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VKCTUQWVWVLYST-OFNKIYASSA-N 0.000 description 1
- LCSVCEOJFVHRIS-MJGOQNOKSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-1,5-naphthyridine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@H](N(C2=CC=C(N=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCSVCEOJFVHRIS-MJGOQNOKSA-N 0.000 description 1
- WGNIXFQMRFUVKZ-KNQAVFIVSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGNIXFQMRFUVKZ-KNQAVFIVSA-N 0.000 description 1
- QLLNXGNTONJQQB-NQIIRXRSSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2h-tetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N=1N=NNC=1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QLLNXGNTONJQQB-NQIIRXRSSA-N 0.000 description 1
- LPEYQFKJCVSIJF-QPPBQGQZSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-cyanoethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CCC#N)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LPEYQFKJCVSIJF-QPPBQGQZSA-N 0.000 description 1
- XWYQUDYLRWEZAC-OFNKIYASSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CCO)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XWYQUDYLRWEZAC-OFNKIYASSA-N 0.000 description 1
- ZXKIBKXDOCBJMP-MJGOQNOKSA-N propan-2-yl (2r,4s)-4-[[3-chloro-5-(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-1,5-naphthyridine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1C[C@H](N(C2=CC=C(N=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(Cl)=CC(C(F)(F)F)=C1 ZXKIBKXDOCBJMP-MJGOQNOKSA-N 0.000 description 1
- NJOMLQFRPPNZOD-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC(C)=C(C(F)(F)F)C=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NJOMLQFRPPNZOD-UHFFFAOYSA-N 0.000 description 1
- VIEUCCBWUICVLI-UHFFFAOYSA-N propan-2-yl 5-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-methyl-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC(C)=CC=C2N(C(=O)OC(C)C)CCCC1N(C(C)=O)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VIEUCCBWUICVLI-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- UTPGOZKRLIRUNN-UHFFFAOYSA-N tert-butyl 4-[2-[4-(5-cyano-1,3-benzoxazol-2-yl)anilino]-2-oxoethoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC(=O)NC1=CC=C(C=2OC3=CC=C(C=C3N=2)C#N)C=C1 UTPGOZKRLIRUNN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The invention provides compositions and methods useful for treating or preventing congestive heart failure, ventricular systolic dysfunction, ventricular diastolic dysfunction or heart failure with preserved ejection fraction, and for reducing risk of congestive heart failure, ventricular systolic dysfunction, ventricular diastolic dysfunction or heart failure with preserved ejection fraction.
Description
METHODS FOR TREATING OR PREVENTING HEART FAILURE AND REDUCING
RISK OF HEART FAILURE
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No.62/815,068, filed March 7, 2019, the disclosure of which is incorporated by reference herein in its entirety. FIELD OF THE INVENTION
[0002] The present disclosure provides compositions and methods useful for treating or preventing congestive heart failure, ventricular systolic dysfunction, ventricular diastolic dysfunction or heart failure with preserved ejection fraction, and for reducing risk of congestive heart failure, ventricular systolic dysfunction, ventricular diastolic dysfunction or heart failure with preserved ejection fraction. BACKGROUND
[0003] Lowering low-density lipoproteins (LDL) is an important therapeutic strategy in the management of cardiovascular disease. Indeed statin drugs, which lower LDL, such as Crestor, Lipitor, Pravachol, and Zocar are widely used and among the most prescribed drugs. For some time it has also been generally accepted that increasing High-density lipoproteins (HDL) could also be therapeutic in cardiovascular disease. Several HDL-raising drugs have been developed including: niacin and CETP inhibitors such as torcetrapib, anacetrapib, evacetrapib and dalcetrapib.
[0004] Cholesteryl ester transfer protein (CETP) also called plasma lipid transfer protein is a hydrophobic glycoprotein that is synthesized in several tissues but mainly in the liver. CETP promotes bidirectional transfer of cholesteryl esters and triglyceride between all plasma lipoprotein particles. The first evidence of the effect of CETP activity on plasma lipoproteins was provided by observations in people with genetic deficiencies of CETP. The first CETP mutation was identified in Japan in 1989 as a cause of markedly elevated HDL-C. Ten mutations associated with CETP deficiency have since been identified in Asians and one in Caucasians. It was found in Japan that 57% of subjects with levels of HDL-C > 100 mg/dL have mutations of the CETP gene. In addition,
37% of Japanese with levels HDL-C between 75-100 mg/dL have mutations of the CETP gene. Subsequently, studies of animals treated with an anti-CETP antibody showed that CETP inhibition resulted in a substantial increase in the concentration of HDL-C. Consistent with these observations in CETP deficient patients and rabbits treated with an anti-CETP antibody, it has since been found that treatment of humans with CETP inhibitor drugs increases the concentration of HDL cholesterol and apoA-I (the major apolipoprotein in HDLs). Numerous epidemiologic studies have correlated the effects of variations in CETP activity with coronary heart disease risk including studies of human mutations (Hirano et al., Curr. Opin. Lipido. (2000) 11(4), 389-396).
[0005] Atherosclerosis and its clinical consequences, including coronary heart disease (CHD), stroke and peripheral vascular disease represents an enormous burden on health care systems internationally. CETP inhibitors have been under development for some time with the expectation that they will be useful for treating or preventing atherosclerosis. A number of classes of CETP inhibitor drugs have been shown to increase HDL, decrease LDL in humans and to have therapeutic effects for treating atherosclerosis and cardiovascular disease including dalcetrapib, torcetrapib, anacetrapib, evacetrapib, BAY 60-5521 and others. However, there is evidence that these drugs may not be safe and effective in all patients. The clinical trial for torcetrapib was terminated in Phase III due to incidence of mortality in patient to whom torcetrapib and atorvastatm were administered concomitantly compared to patients treated with atorvastatin alone. The clinical trial for dalcetrapib was also halted in Phase III in this case due to a lack of efficacy relative to statins alone.
[0006] The dalcetrapib mortality and morbidity trial (dal-OUTCOMES) was a double-blind, randomized, placebo-controlled, parallel group, multi-centre study in stable CHD patients recently hospitalized for acute coronary syndrome (ACS). The study was conducted to test the hypothesis that CETP inhibition will reduce the risk of recurrent cardiovascular events in patients with recent ACS by raising levels of HDL-C through CETP inhibition. Eligible patients entered a single-blind placebo run-in period of approximately 4 to 6 weeks to allow for patients to stabilize and for completion of planned revascularization procedures. At the end of the run-in period, eligible patients in stable condition were randomized in a 1: 1 ratio to 600 mg of dalcetrapib or placebo on top of evidence-based medical care for ACS. The dal-OUTCOMES study resulted in unexpected observations related to cardiovascular disease progression. Despite a marked increase in HDL-c,
patients on treatment did not show a significant reduction in cardiovascular events and the study was terminated.
[0007] A pharmacogenomic study of the dal-OUTCOMES study population was conducted to study the inter-individual variation in dalcetrapib response and to identify genetic markers for predicting therapeutic response to dalcetrapib, or other CETP inhibitors, for patient stratification and for treatment selection. It was discovered that the effects of dalcetrapib on atherosclerotic outcomes are determined by correlated polymorphisms in the Adenylate Cyclase Type 9 (ADCY9) gene. Specifically, 20 SNPs that occur in the ADCY9 gene on chromosome 16, including rs11647778, rs1967309, rs12595857, rs2239310, rs11647828, rs8049452, rsl2935810, rs74702385, rs17136707, rs8061182, rs111590482, rs4786454, rs2283497, rs2531967, rs3730119, rs2531971, rs2238448, rsl1599911, rs12920508, and rsl3337675 were found to be associated with response to a CETP inhibitor, dalcetrapib. In particular rs11647778 or rsl967309 are both in strong linkage disequilibrium together (r2=0.79) and strongly associated with response to dalcetrapib. This finding was disclosed in WO2014154606A1, WO2016016157A1, Tardif et al., Circulation: Cardiovascular Genetics, (2015) 8:372-382, and Tardif et al., Circulation: Cardiovascular Genetics, (2016) 9:340-348, each of which is incorporated by reference herein.
[0008] Adenylate cyclases (ADCYs) catalyze the formation of cyclic adenosine-3¢,5¢- monophosphate (cAMP), the universal second messenger, from adenosine triphosphate (ATP). The adenylate cyclase family consists of 10 members (ADCY1-ADCY10) with high primary sequence similarity at the catalytic site. ADCY9 is the ninth, least well characterized and widely distributed isoform of adenylate cyclase. Polymorphisms in the ADCY9 gene have been shown to affect individual response to inhaled therapy in patients with asthma. (Kim et al., J Clin Pharm Ther. (2011) 36:399–405) Recently, another ADCY9 gene polymorphism was shown to be associated with bodymass index and clinical classes of obesity. (Berndt et al., Nat Genet. (2013) 45:501–512) However, the underlying mechanisms responsible for the interaction between ADCY9 and CETP has not yet been previously disclosed. There is still a need to develop novel therapeutic compositions and methods for treatment or prophylaxis of subject with cardiovascular disorder.
SUMMARY OF THE INVENTION
[0009] One aspect of the invention provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0010] Another aspect of the invention provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0011] Another aspect of the invention provides methods for reducing risk of diastolic heart failure, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[0012] Another aspect of the invention provides methods for reducing the risk of diastolic heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[0013] Another aspect of the invention provides methods for reducing risk of systolic heart failure, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[0014] Another aspect of the invention provides methods for reducing risk of systolic heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the
congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[0015] Another aspect of the invention provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0016] Another aspect of the invention provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0017] Another aspect of the invention provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0018] Another aspect of the invention provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0019] Another aspect of the invention provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0020] Another aspect of the invention provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0021] Another aspect of the invention provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0022] Another aspect of the invention provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0023] Another aspect of the invention provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0024] Another aspect of the invention provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[0025] Another aspect of the invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[0026] Another aspect of the invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIG. 1A shows that Adcy9 mRNA expression (analyzed by RT-qPCR) in the heart was decreased by 50% in Adcy9WT/Gt mice and by at least 90% in Adcy9Gt/Gt mice compared to WT (wild type). FIG. 1E shows that ADCY9 protein expression was abolished in Adcy9Gt/Gt mice compared to WT in the skeletal muscle.
[0028] FIG.1B shows the plasma PCSK9 concentration of WT and Adcy9Gt/Gt mice infected with AAV8-Pcsk9D377Y at baseline, one week after infection and before the start of the atherogenic diet, after 8 weeks and 12 weeks of atherogenic diet.
[0029] FIG. 1C shows that PCSK9D377Y induced a reduction of 90% in hepatic LDL receptor expression that was similar in WT and Adcy9Gt/Gt.
[0030] FIG. 1D shows the plasma cholesterol levels of WT and Adcy9Gt/Gt mice infected with AAV8-Pcsk9D377Y at baseline, one week after infection and before the start of the atherogenic diet, after 4 weeks, 8 weeks and 12 weeks of atherogenic diet.
[0031] FIG. 2A and FIG. 2B show the lipoprotein profile by chromatography of WT (FIG. 2A) and Adcy9Gt/Gt (FIG.2B) mice at baseline and after 16 weeks of atherogenic diet.
[0032] FIG. 3A shows that 11.3±2.1% of the surface of the intima covered with atherosclerotic lesions in WT mice compared to 3.8±0.6% in Adcy9Gt/Gt mice at sacrifice. Atherosclerosis lesions were quantified on whole aorta dissected en face. FIG. 3D shows atherosclerotic lesions in the aorta of WT and Adcy9Gt/Gt mice as revealed by Oil Red O staining.
[0033] FIG. 3B shows that the cross-sectional quantification of plaque area all along the aortic root of WT and Adcy9Gt/Gt mice. FIG.3E shows the atherosclerotic lesions in cross-sections of the aortic valve of WT and Adcy9Gt/Gt mice.
[0034] FIG.3C and FIG.3F show that all WT animals had plaques in the brachiocephalic arteries in contrast to Adcy9Gt/Gt mice (100%, versus 50%, P<0.05). The plaques in WT mice were also larger and presented more frequently fibrin deposits at their surface (P<0.05) and cap ruptures compared to Adcy9Gt/Gt mice.
[0035] FIG.4A shows that CD68-positive foam cells, a key constituent of atherosclerotic plaques, represented 19.0±1.9% and 11.4±2.1% of the lesion area in WT and Adcy9Gt/Gt mice, respectively
(P<0.05). FIG. 4D shows immune-fluorescent detection of CD68-positive macrophages (foam cells).
[0036] FIG.4B shows in situ hybridization analysis of Adcy9 expression in atherosclerotic lesions at sites of foam cell accumulation in WT and Adcy9Gt/Gt mice.
[0037] FIG. 4C and FIG. 4E show immunofluorescence detection of Ki67 which revealed that proliferation of CD68-positive foam cells was significantly decreased in Adcy9Gt/Gt compared to WT (P<0.05).
[0038] FIG.5A shows that endothelial-dependent vasodilatation to ACh in untreated animals (no AAV8-Pcsk9D377Y and no atherogenic diet) was potentiated in the femoral arteries of Adcy9Gt/Gt mice compared to WT (P<0.01); in contrast, endothelial-independent vasodilation to the nitric oxide donor SNP was similar in both groups (FIG.5E).
[0039] FIG. 5B shows that Adcy9 inactivation also potentiated endothelial-dependent vasodilatation in response to increased shear stress (15 dynes/cm2) compared to WT (42.3±7.1% versus 28.2±6.3%, P=0.08).
[0040] FIG. 5C and FIG.5F show that in femoral arteries from atherosclerotic animals (AAV8- Pcsk9D377Y and atherogenic diet) both endothelial-dependent (Ach) and endothelial-independent vasodilatation (SNP) were increased in Adcy9Gt/Gt mice compared to WT mice (P<0.05).
[0041] FIG. 5D and FIG. 5G show that the relaxant dose response to ACh (FIG. 5D) and SNP (FIG. 5G) of aorta of animals treated with the AAV8-Pcsk9D377Y and atherogenic diet when comparing Adcy9Gt/Gt to WT mice.
[0042] FIG. 6A and FIG. 6D show that the nitric oxide synthase blocker L-NNA inhibited significantly ACh-induced vasodilatation both in WT and Adcy9Gt/Gt mice (P<0.01), but flow- mediated vasodilatation was numerically reduced only in Adcy9Gt/Gt mice.
[0043] FIG.6B and FIG.6E show that the cyclooxygenase blocker meclofenamate or the cocktail of endothelial-dependent hyperpolarization blockers (TRAM-34 and apamin), inhibited ACh- induced endothelial-dependent vasodilatation in Adcy9Gt/Gt mice (P<0.01 for both pathways) but not in WT mice.
[0044] FIG. 6C shows the specificity of the Adcy9 mRNA signal by in situ hybridization in the femoral artery wall was confirmed by absence of dots with the negative control probe.
[0045] FIG. 7A shows that Adcy9Gt/Gt mice gained more weight than WT animals during the 16 weeks of atherogenic diet, to reach weights of 45.1±2.4 g and 33.5±1.2 g respectively (P<0.01).
[0046] FIG. 7B shows that MRI performed at week 14 showed that Adcy9Gt/Gt mice presented more adipose tissue than WT mice.
[0047] FIG.7C shows a doubling of total body adipose tissue volume in Adcy9Gt/Gt mice (9.4±1.2 cm3) compared to WT (4.3±0.4 cm3, P<0.01).
[0048] FIG. 7D shows larger inguinal, perirenal, epididymal and interscapular fat depots in Adcy9Gt/Gt mice compared to WT.
[0049] FIG. 7E and FIG.7F show histological sections showing that Adcy9 inactivation resulted in hypertrophic adipocytes in epididymal white adipose tissue (FIG.7E) and larger lipid droplets in interscapular brown adipose tissue (FIG.7F).
[0050] FIG. 8A shows that with the atherogenic diet, Adcy9Gt/Gt mice showed a significant increase in feed efficiency (1.2±0.1 g/100 kCal) compared to WT (0.6±0.1 g/100 kCal, P<0.01).
[0051] FIG.8B shows RR interval (representing heart rate variability by telemetry) was increased in Adcy9Gt/Gt mice (135±5 ms) compared to WT mice (123±4 ms, P=0.05).
[0052] FIG. 8C shows that nocturnal heart rate was lower in Adcy9Gt/Gt mice (447±10 bpm) compared to WT mice (475±10 bpm, P=0.06). pNN(6), which represents the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity17, was increased during the night period in Adcy9Gt/Gt mice (21.6±2.4%) compared to WT (14.5±2.2%, P<0.05).
[0053] FIG. 9A and FIG. 9C show that CETPWT and CETPGt mice developed similar atherosclerotic lesions that covered 11.8±1.8% and 8.6±1.9% of the intima area, respectively (P=NS).
[0054] FIG. 9B shows percentage of lesion area in the whole aorta in WT, Adcy9Gt/Gt, CETPWT and CETPGt mice.
[0055] FIG. 10A shows vasodilatation to ACh in femoral arteries from atherosclerotic CETPWT and CETPGt mice.
[0056] FIG. 10B shows vasodilatation to SNP in femoral arteries from atherosclerotic CETPWT and CETPGt mice.
[0057] FIG.11A shows progression of body weight upon atherogenic treatment in WT, Adcy9Gt/Gt, CETPWT and CETPGt mice.
[0058] FIG.11B shows adipose tissue volumes on MRI in WT, Adcy9Gt/Gt, CETPWT and CETPGt mice.
[0059] FIG. 12A depicts mice model of myocardial infarction. These mice have four different genotypes: WT (wild-type mice); Adcy9Gt/Gt (Adyc9 gene-trapped mice); tgCETP+/- (transgenic mice carrying a copy of CETP gene); and Adcy9Gt/Gt - tgCETP+/- (Adyc9 gene-trapped mice carrying a copy of CETP gene). All mice were have a C57BL/6J genetic background.
[0060] FIG. 12B is a diagram showing ligation of the left ventricular anterior descending (LAD) artery using a suture, used to mimic the myocardial infarction caused by plaque formation.
[0061] FIG. 12C depicts a surgical timeline of a mouse infarction model by ligating the LAD. Echocardiography (“Echo”) was performed at baseline, at 24 hours, at 1 week, and before 4 weeks postoperatively.
[0062] FIG.13A shows Kruskal-Wallis tests of the age of the mice with the four genotypes at day 0.
[0063] FIG.13B shows Kruskal-Wallis tests of the body weight (“BW”) of the mice with the four genotypes at day 0.
[0064] FIG.13C shows survival of the mice in 28 days. No differences in survival among the mice with the four genotypes were observed.
[0065] FIG.14A (all mice) and FIG.14B (alive mice only) show echocardiographic wall motion score index (WMSI) analysis that was performed at 24 hours post-LAD-ligation for sham or myocardial-infarction-induced (“MI”) mice with the four genotypes (WT, Adcy9Gt/Gt, tgCETP+/- and Adcy9Gt/Gt - tgCETP+/-).
[0066] FIG.15 shows WMSI correlated with serum cardiac troponin‐I (cTn-I) at 24 hours.
[0067] FIG. 16A shows that the reduced WMSI for Adcy9Gt/Gt mice observed at 24 hours post- LAD-ligation is maintained over-time.
[0068] FIG. 16B shows two-way repeated ANOVA analysis for myocardial-infarction-induced (“MI”) mice with the four genotypes (WT, Adcy9Gt/Gt, tgCETP+/- and Adcy9Gt/Gt - tgCETP+/-) (p<0.001).
[0069] FIG.17A shows how the portion of ischemic myocardium was calculated.
[0070] FIG.17B shows proportion of ischemic myocardium in mice with the four genotypes.
[0071] FIG. 18A shows how the hearts of the mice with the four genetic backgrounds were sectioned for histological analysis.
[0072] FIG.18B shows Masson's trichrome staining of the heart for infarct size estimation.
[0073] FIG.19A and FIG.19B show infarct-size-reduction in mice with the four genotypes (WT, Adcy9Gt/Gt, tgCETP+/- and Adcy9Gt/Gt - tgCETP+/-).
[0074] FIG. 19C shows that Adcy9Gt/Gt MI mice had a lower WMSI compared to the mice with the other genotypes.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0075] An“effective amount,” when used in connection with a CETP inhibitor and an ADCY inhibitor, is the total amount of CETP inhibitor and ADCY inhibitor that is effective for treating or preventing a cardiovascular disorder or reducing risk of a cardiovascular event in a subject.
[0076] A“gene” is an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a specific functional product and may include untranslated and untranscribed sequences in proximity to the coding regions. Such non-coding sequences may contain regulatory sequences needed for transcription and translation of the sequence or introns etc. or may as yet to have any function attributed to them beyond the occurrence of the SNP of interest.
[0077] The term“genotyping” refers to the determination of the genetic information an individual carries at one or more positions in the genome. For example, genotyping may comprise the determination of which allele or alleles an individual carries for a single SNP or the determination of which allele or alleles an individual carries for a plurality of SNPs. For example, at rs 1967309
the nucleotides may be an A in some individuals and a G in other individuals. Those individuals who have an A at the position have the A allele and those who have a G have the G allele. In a diploid organism the individual will have two copies of the sequence containing the polymorphic position so the individual may have an A allele and a G allele or alternatively, two copies of the A alleles or two copies of the G allele. Those individuals who have two copies of the G allele are homozygous for the G allele, those individuals who have two copies of the A allele are homozygous for the A allele, and those individuals who have one copy of each allele are heterozygous. The alleles are often referred to as the A allele, often the major allele, and the B allele, often the minor allele. The genotypes may be AA (homozygous A), BB (homozygous B) or AB (heterozygous).
[0078] The term“about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, the language“about 50” means from 45 to 55.
[0079] The term“subject,” as used herein unless otherwise defined, is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, or baboon. In some embodiments, the subject is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[0080] As used herein, the term“adult human” refers to a human that is 18 years or older.
[0081] As used herein, the term“pediatric human” refers to a human that is 1 year to 18 years old. CEPT Inhibitors
[0082] CETP inhibitors that are useful in the compositions and methods of the invention include small molecules, anti-CETP antibodies and peptides that inhibit or suppress CETP activity.
[0083] CETP inhibitors that are useful in the compositions and methods of the invention include, but are not limited to, dalcetrapib, anacetrapib, evacetrapib, torcetrapib, BAY 60-5521, obicetrapib, BMS-795311, CP-800,569, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19- 4789, BAY 38-1315, DLBS-1449 (Dexa Medica) and ATH-03 (Affris), and pharmaceutically acceptable salts of any of the foregoing.
[0084]“Dalcetrapib” refers to S-[2-({[1-(2-Ethylbutyl)cyclohexyl]carbonyl}amino)phenyl]-2- methylpropanethioate, and is also known as JTT-705 or CAS 211513-37-0. Dalcetrapib has the structure:
[0085]“Anacetrapib” refers to (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'- methoxy-5'- (propan-2-yl)-4-(trifluoromethyl)[1,l'-biphenyl]-2-yl]methyl}-4-methyl-1,3- oxazolidin-2-one, and is also known as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4- fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3- oxazolidin-2-one; MK-0859; or CAS 875446-37-0. Anacetrapib has the structure:
[0086]“Evacetrapib” refers to trans-4-({(5S)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2- methyl-2H-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-lH-benzazepin-l- yl}methyl)cyclohexanecarboxylic acid, and is also known as LY2484595 or CAS 1186486-62-3. Evacetrapib has the structure:
[0087] “Torcetrapib” refers to (2R,4S)-4-[(3,5-bistrifluoromethylbenzyl) methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid ethyl ester, and is also known as Ethyl (2R,4S)-4-({[3,5- bis(trifluoromethyl)phenyl]methyl}(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)- 1,2,3,4-tetrahydroquinoline-1-carboxylate; CP-529,414; or CAS 262352-17-0. Torcetrapib has the structure:
[0088]“BAY 60-5521” refers to (S)-4-cyclohexyl-2-cyclopentyl-3-((S)-fluoro(4- (trifluoromethyl)phenyl)methyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol, and is also known as CAS 893409-49-9. BAY 60-5521 has the structure:
[0089]“Obicetrapib” refers to 4-((2-((3,5-bis(trifluoromethyl)benzyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)pyrimidin- 5-yl)oxy)butanoic acid, and is also known as AMG-899, DEZ-001, TA-8995 or CAS 866399-87- 3. Obicetrapib has the structure:
[0090]“BMS795311” refers to (R)-N-(1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5- (2,2,3,3-tetrafluoropropanoyl)phenyl)-2-phenylethyl)-4-fluoro-3-(trifluoromethyl)benzamide, and is also known as CAS 939390-99-5. BMS795311 has the structure:
[0091]“CP-800,569” refers to (2R)-3-[3-(4-chloro-3-ethylphenoxy)-n-[[3-(1,1,2,2- tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol. CP-800,569 has the structure:
[0092]“DRL-17822” refers to CAS 1454689-50-9 and is disclosed in WO 2014128564 and WO 2014076568. DRL-17822 has the structure:
[0093]“JNJ-28545595” refers to 1,1,1-Trifluoro-3-[2-[3-(1,1,2,2-tetra-fluoroethoxy)phenyl]-5- (3-trifluoromethoxyphenyl)-3,4-dihydro-2H-quinolin-1-yl]-propan-2-ol.
[0094]“JNJ-28614872” refers to 1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8- (3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol.
[0095] The structure of JNJ-28545595 and JNJ-28614872 is set forth below:
[0096] The structure of“BAY 19-4789” and“BAY 38-1315” is set forth below:
[0097] Additional CETP inhibitors useful in the compositions and methods of the invention include those disclosed in WO 2016/086453 or Chen et al., European Journal of Medicinal Chemistry, (2017) 139:201-213, and have the structure:
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing; and
and pharmaceutically acceptable salts of the foregoing.
[0098] Additional CETP inhibitors useful in the compositions and methods of the invention are disclosed in WO 2016/086453 or Chen et al. and include, but are not limited to:
and pharmaceutically acceptable salts of the foregoing.
[0099] Further CETP inhibitors useful in the compositions and methods of the invention include those disclosed in WO 2017/011279, and have the structure:
and pharmaceutically acceptable salts of the foregoing.
[00100] Still other CETP inhibitors useful in the compositions and methods of the invention include those disclosed in WO 2016/018729, and have a structure according to the following:
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts thereof;
and pharmaceutically acceptable salts of the foregoing; and
and pharmaceutically acceptable salts of the foregoing.
[00101] Additional CETP inhibitors useful in the compositions and methods of the invention are disclosed in US 7,781,426, including, but not limited to:
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing; and
and pharmaceutically acceptable salts of the foregoing.
[00102] Additional CETP inhibitors useful in the compositions and methods of the invention are disclosed in US 7,652,049, including, but not limited to:
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing;
and pharmaceutically acceptable salts of the foregoing; and
and pharmaceutically acceptable salts of the foregoing.
[00103] Additional CETP inhibitors useful in the compositions and methods of the invention are disclosed in US20150374675 A1 and include, but are not limited to:
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate;
S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;
S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;
S-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;
O-methyl S-[2-(1-isopentylcyclohexanecarbonylamino phenyl monothiocarbonate;
S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;
S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;
S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;
S-[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;
S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;
S-[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2-dimethylthiopropionate;
S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate;
S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis- [4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;
2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;
N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;
N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;
N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;
N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;
S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate; bis-[2-[1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;
N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;
S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;
S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;
S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4-thiocarboxylate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;
S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;
S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;
S-[2-1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;
S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; and
S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate; and pharmaceutically acceptable salts of the foregoing.
[00104] Additional examples of CETP inhibitors useful in the compositions and methods of the invention include, but are not limited to: torcetrapib; dalcetrapib; anacetrapib; evacetrapib; obicetrapib; BMS-79531; CP-800,569; DRL-17822; JNJ-28545595; JNJ-28614872; BAY 19- 4789; BAY 38-1315; 1,1,1-trifluoro-3-((3-phenoxyphenyl)(3-(1,1,2,2- tetrafluoroethoxy)benzyl)amino)propan-2-ol; (R)-3-((4-(4-chloro-3-ethylphenoxy)pyrimidin-2- yl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol; (R)-3-((3-(4-chloro-3- ethylphenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol (CP-800,569); N-(4-(5,7-dimethylbenzo[d]oxazol-2-yl)phenyl)-2-(o-tolyloxy)acetamide; 2-(4- chloro-2,3-dimethylphenoxy)-N-(4-(5-cyanobenzo[d]oxazol-2-yl)phenyl)acetamide; N-(4-(5- chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-tolyloxy)acetamide; N-(4-(5-chlorobenzo[d]oxazol-2- yl)phenyl)-2-(o-tolyloxy)acetamide; N-(4-(5-cyano-7-methylbenzo[d]oxazol-2-yl)phenyl)-2-(o- tolyloxy)acetamide; N-(4-(5-cyano-7-(2-hydroxypropan-2-yl)benzo[d]oxazol-2-yl)phenyl)-2-(o- tolyloxy)acetamide; 2-(4-((2-(3,3,3-trifluoro-2-methyl-2- (trifluoromethyl)propoxy)ethyl)amino)phenyl)benzo[d]oxazole-5-carbonitrile; tert-butyl 4-(2-((4- (5-cyanobenzo[d]oxazol-2-yl)phenyl)amino)-2-oxoethoxy)piperidine-1-carboxylate; N-(4-(5- cyano-7-methylbenzo[d]oxazol-2-yl)phenyl)-2-(4-(3-(trifluoromethyl)phenyl)piperazin-1- yl)acetamide; N-(4-(5-cyano-7-methylbenzo[d]oxazol-2-yl)phenyl)-2-(4-(4- (trifluoromethyl)phenyl)piperazin-1-yl)acetamide; N-(4-(5-cyano-7-methylbenzo[d]oxazol-2- yl)phenyl)-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)acetamide; 4-(5-cyano-7- methylbenzo[d]oxazol-2-yl)-N-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)benzamide; 4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4- yl)methyl)benzamide; 4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-phenylpyridin-2- yl)piperidin-4-yl)methyl)benzamide; 4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-(2- isopropyl-5-methylphenyl)pyridin-2-yl)piperidin-4-yl)methyl)benzamide; 4-(5-cyano-7- isopropylbenzo[d]oxazol-2-yl)-N-((1-(5-(5-fluoro-2-isopropylphenyl)pyridin-2-yl)piperidin-4- yl)methyl)benzamide; (R)-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((2-oxo-3-(5-(2- (trifluoromethoxy)phenyl)pyridin-2-yl)oxazolidin-5-yl)methyl)benzamide; (S)-4-(5-cyano-7- isopropylbenzo[d]oxazol-2-yl)-N-((2-oxo-3-(5-(2-(trifluoromethoxy)phenyl)pyridin-2- yl)oxazolidin-5-yl)methyl)benzamide; (R)-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((5- methyl-2-oxo-3-(5-(2-(trifluoromethoxy)phenyl)pyridin-2-yl)oxazolidin-5-yl)methyl)benzamide; (S))-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)-N-((5-methyl-2-oxo-3-(5-(2-
(trifluoromethoxy)phenyl)pyridin-2-yl)oxazolidin-5-yl)methyl)benzamide; N-((4-(4-(tert- butyl)phenyl)cyclohexyl)methyl)-4-(5-cyano-7-isopropylbenzo[d]oxazol-2-yl)benzamide;
methyl (3,5-bis(trifluoromethyl)benzyl)((5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'- biphenyl]-2-yl)methyl)carbamate; methyl (3,5-bis(trifluoromethyl)benzyl)(2- ((ethoxycarbonyl)(propyl)amino)-5-(trifluoromethyl)benzyl)carbamate; methyl (3,5- bis(trifluoromethyl)benzyl)(2-(2-oxooxazolidin-3-yl)-5-(trifluoromethyl)benzyl)carbamate; methyl (3,5-bis(trifluoromethyl)benzyl)(2-(2-oxoimidazolidin-1-yl)-5- (trifluoromethyl)benzyl)carbamate; 4-(3,5-bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'- methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)oxazolidin-2-one; (R)-4-(3,5- bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2- yl)methyl)oxazolidin-2-one; (S)-4-(3,5-bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'-methoxy- 4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)oxazolidin-2-one; (4R,5S)-5-(3,5- bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2- yl)methyl)-4-methyloxazolidin-2-one; (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5'- isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2- one; (4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'-methoxy-4-(trifluoromethyl)- [1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one; (4S,5S)-5-(3,5- bis(trifluoromethyl)phenyl)-3-((5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2- yl)methyl)-4-methyloxazolidin-2-one; 5-(2,6-bis(trifluoromethyl)pyridin-4-yl)-3-((4'-fluoro-5'- isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2- one; (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-2'-hydroxy-5'-isopropyl-4- (trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one; (4S,5S)-5-(3,5- bis(trifluoromethyl)phenyl)-3-((4'-fluoro-2',3'-dihydroxy-5'-isopropyl-4-(trifluoromethyl)-[1,1'- biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one; (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3- ((4'-fluoro-2',3'-dihydroxy-5'-(2-hydroxypropan-2-yl)-4-(trifluoromethyl)-[1,1'-biphenyl]-2- yl)methyl)-4-methyloxazolidin-2-one; (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro- 5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)-4- methyloxazolidin-2-one; N-(6'-(((4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2- oxooxazolidin-3-yl)methyl)-2-methoxy-4',4'-dimethyl-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)- N-methylacetamide; (S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'- methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4,4-dimethyloxazolidin-2-one; 3-(6'-
(((4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-2-methoxy- 4',4'-dimethyl-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)-2,2-dimethylpropanoic acid; 3-(3-(2- (((4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-6- methoxypyridin-3-yl)-4-methoxyphenyl)propanoic acid; 3'-(6-(azetidin-1-yl)-2-(((4S,5S)-5-(3,5- bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)pyridin-3-yl)-5'-fluoro-4'- methoxy-2-methyl-[1,1'-biphenyl]-4-carboxylic acid; isopropyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(2H-tetrazol-5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4- dihydroquinoline-1(2H)-carboxylate; isopropyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2- methyl-2H-tetrazol-5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)- carboxylate; isopropyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2-(2-cyanoethyl)-2H-tetrazol- 5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; isopropyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2-(2-hydroxyethyl)-2H-tetrazol-5-yl)amino)-2-ethyl- 6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; isopropyl (2R,4S)-4-((2-(2- aminoethyl)-2H-tetrazol-5-yl)(3,5-bis(trifluoromethyl)benzyl)amino)-2-ethyl-6- (trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; isopropyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(2-(2-hydroxypropyl)-2H-tetrazol-5-yl)amino)-2-ethyl-6- (trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4- dihydroquinoline-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2- methyl-2H-tetrazol-5-yl)amino)-2-ethyl-8-methyl-6-(trifluoromethyl)-3,4-dihydroquinoline- 1(2H)-carboxylate; ethyl (2R,4S)-4-(N-(3,5-bis(trifluoromethyl)benzyl)acetamido)-2-ethyl-6- (trifluoromethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate; ethyl (2R,4S)-4-(N-(3,5- bis(trifluoromethyl)benzyl)acetamido)-2-ethyl-6-methoxy-3,4-dihydro-1,5-naphthyridine-1(2H)- carboxylate; ethyl (2R,4S)-4-(N-(3,5-bis(trifluoromethyl)benzyl)acetamido)-6-(dimethylamino)- 2-ethyl-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4- dihydro-1,5-naphthyridine-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-2-ethyl-6-methoxy-3,4-dihydro- 1,5-naphthyridine-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2- methyl-2H-tetrazol-5-yl)amino)-6-(dimethylamino)-2-ethyl-3,4-dihydro-1,5-naphthyridine- 1(2H)-carboxylate; isopropyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-
5-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate;
isopropyl (2R,4S)-4-((3-chloro-5-(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-2- ethyl-6-(trifluoromethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate; isopropyl (2R,4S)-4- ((3,5-dichlorobenzyl)(2-methyl-2H-tetrazol-5-yl)amino)-2-ethyl-6-methyl-3,4-dihydro-1,5- naphthyridine-1(2H)-carboxylate; 5-(((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5- yl)amino)methyl)-N-(cyclopentylmethyl)-N-ethyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6- amine; 6-(((2-(bis(cyclopropylmethyl)amino)-7,7-dimethyl-6,7-dihydro-5H- cyclopenta[b]pyridin-3-yl)methyl)(3,5-bis(trifluoromethyl)benzyl)amino)benzo[d]oxazol-2(3H)- one; 3-(((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)methyl)-N,N- bis(cyclopropylmethyl)-7,7-dimethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-2-amine; isopropyl (2R)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2- ethylpyrrolidine-1-carboxylate; 3-(((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5- yl)amino)methyl)-5-bromo-N-(cyclopentylmethyl)-N-ethyl-6-methylpyridin-2-amine; 3-(((3,5- bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)methyl)-N-(cyclopentylmethyl)-N- ethyl-6-methyl-5-(methylthio)pyridin-2-amine; ((2R)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1- methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2-ethylpyrrolidin-1-yl)(cyclohexyl)methanone; (1r,4r)-4-(((2-(((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)methyl)-4- (trifluoromethyl)phenyl)(ethyl)amino)methyl)cyclohexane-1-carboxylic acid; 3-((((3- ((cyclopentylmethyl)(ethyl)amino)-5,6,7,8-tetrahydronaphthalen-2-yl)methyl)(2-methyl-2H- tetrazol-5-yl)amino)methyl)-5-(trifluoromethyl)benzonitrile; (1R,4r)-4-(((2R,6S)-4-((3,5- bis(trifluoromethyl)benzyl)(5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6- diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic acid; (1R,3R)-3-(((2R,6S)-4-((3,5- bis(trifluoromethyl)benzyl)(5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6- diethylpiperidine-1-carbonyl)oxy)cyclobutane-1-carboxylic acid; 1-(2-((3,5- bis(trifluoromethyl)benzyl)(2-(ethyl(2-methoxyethyl)amino)benzyl)amino)pyrimidin-5- yl)piperidine-4-carboxylic acid; 5-(((1-(3,5-bis(trifluoromethyl)phenyl)ethyl)(5-(2- (methylsulfonyl)ethoxy)pyrimidin-2-yl)amino)methyl)-N-(cyclopentylmethyl)-N-ethyl-1,3- dimethyl-1H-indazol-6-amine; N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-N-(2- ((cyclopentylmethyl)(ethyl)amino)-5-(trifluoromethyl)benzyl)-5-(2- (methylsulfonyl)ethoxy)pyrimidin-2-amine; 4-((2-((3,5-bis(trifluoromethyl)benzyl)((3- ((cyclopropylmethyl)(propyl)amino)quinolin-2-yl)methyl)amino)pyrimidin-5-yl)oxy)butanoic
acid; 3-((((3-((cyclopentylmethyl)(ethyl)amino)-6-methoxypyridin-2-yl)methyl)(5-(2- (methylsulfonyl)ethoxy)pyrimidin-2-yl)amino)methyl)-5-(trifluoromethyl)benzonitrile; 2- ((1S,4r)-4-(((2-((((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)(5-(2- (methylsulfonyl)ethoxy)pyrimidin-2-yl)amino)methyl)-4- (trifluoromethyl)phenyl)(ethyl)amino)methyl)cyclohexyl)acetic acid; ethyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(5-(2-(methylsulfonyl)ethoxy)pyrimidin-2-yl)amino)-2-ethyl-6- methoxy-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5- bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2-ethyl-6-(trifluoromethyl)-3,4- dihydroquinoline-1(2H)-carboxylate; ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(5- morpholinopyrimidin-2-yl)amino)-2-ethyl-6-methoxy-3,4-dihydro-1,5-naphthyridine-1(2H)- carboxylate; isopropyl 5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7- methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carboxylate; isopropyl 5- (N-(3,5-bis(trifluoromethyl)benzyl)acetamido)-7-methyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine- 1-carboxylate; 3-(5-(4-chloro-3-ethylphenoxy)-2-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-3,4- dihydroquinolin-1(2H)-yl)-1,1,1-trifluoropropan-2-ol; (S)-1,1,1-trifluoro-3-((R)-2-(3-(1,1,2,2- tetrafluoroethoxy)phenyl)-5-(4-(trifluoromethoxy)phenyl)-3,4-dihydroquinolin-1(2H)-yl)propan- 2-ol (JNJ-28545595); (S)-1,1,1-trifluoro-3-((S)-3-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-8-(4- (trifluoromethoxy)phenyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)propan-2-ol (JNJ- 28614872); (R)-3-((R)-4-(3-(difluoromethoxy)benzyl)-2-(3-(trifluoromethyl)phenyl)-3,4- dihydroquinoxalin-1(2H)-yl)-1,1,1-trifluoropropan-2-ol; (S)-(2-cyclopentyl-4-ethyl-5-hydroxy- 7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanone; (S)-2- cyclopentyl-3-((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-4-(4-fluorophenyl)-7,7-dimethyl- 5,6,7,8-tetrahydroquinolin-5-ol (BAY 19-4789); (S)-3'-((S)-fluoro(4- (trifluoromethyl)phenyl)methyl)-4'-(4-fluorophenyl)-2'-isopropyl-5',8'-dihydro-6'H- spiro[cyclobutane-1,7'-quinolin]-5'-ol (BAY 38-1315); (S)-4-cyclohexyl-2-cyclopentyl-3-((S)- hydroxy(4-(trifluoromethyl)phenyl)methyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol; (S)-4- cyclohexyl-2-cyclopentyl-3-((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-7,7-dimethyl-5,6,7,8- tetrahydroquinolin-5-ol; (S)-4-cyclohexyl-2-cyclopentyl-7,7-dimethyl-3-(4- (trifluoromethyl)benzyl)-5,6,7,8-tetrahydroquinolin-5-ol; (S)-6'-((S)-fluoro(4- (trifluoromethyl)phenyl)methyl)-5'-(4-fluorophenyl)-7'-isopropyl-3',4'-dihydrospiro[cyclobutane- 1,2'-pyrano[2,3-b]pyridin]-4'-ol; (S)-6'-((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-5'-(4-
fluorophenyl)-7'-isopropyl-3',4'-dihydrospiro[cyclopropane-1,2'-pyrano[2,3-b]pyridin]-4'-ol; (S)- 5'-(4-fluorophenyl)-6'-((S)-hydroxy(4-(trifluoromethyl)phenyl)methyl)-7'-isopropyl-3',4'- dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-ol; (S)-5'-(4-fluorophenyl)-6'-((S)- hydroxy(4-(trifluoromethyl)phenyl)methyl)-7'-isopropyl-3',4'-dihydrospiro[cyclopropane-1,2'- pyrano[2,3-b]pyridin]-4'-ol; (S)-(2-cyclopentyl-5-hydroxy-4-isopropyl-7,7-dimethyl-5,6,7,8- tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanone; (S)-(2-cyclopentyl-5-hydroxy- 7,7-dimethyl-4-(penta-1,3-diyn-1-yl)-5,6,7,8-tetrahydroquinolin-3-yl)(4- (trifluoromethyl)phenyl)methanone compound with dihydrogen (1:3); (S)-(2-cyclopentyl-4- (hexa-1,3,5-triyn-1-yl)-5-hydroxy-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4- (trifluoromethyl)phenyl)methanone compound with dihydrogen (1:5); (S)-(2'-cyclopentyl-5'- hydroxy-4'-isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinolin]-3'-yl)(4- (trifluoromethyl)phenyl)methanone; (S)-(2'-cyclopentyl-5'-hydroxy-4'-(penta-1,3-diyn-1-yl)- 5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinolin]-3'-yl)(4-(trifluoromethyl)phenyl)methanone compound with dihydrogen (1:3); (S)-(2'-cyclopentyl-4'-(hexa-1,3,5-triyn-1-yl)-5'-hydroxy-5',8'- dihydro-6'H-spiro[cyclobutane-1,7'-quinolin]-3'-yl)(4-(trifluoromethyl)phenyl)methanone compound with dihydrogen (1:5); (S)-(4-cyclohexyl-5-hydroxy-2-isopropyl-7,7-dimethyl-5,6,7,8- tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanone; (S)-(4'-cyclohexyl-5'-hydroxy-2'- isopropyl-5',8'-dihydro-6'H-spiro[cyclobutane-1,7'-quinolin]-3'-yl)(4- (trifluoromethyl)phenyl)methanone; (S)-4-(4,4-difluorocyclohexyl)-3-((S)-fluoro(4- (trifluoromethyl)phenyl)methyl)-2-(1-(5-(3-hydroxy-3-methylbutoxy)pyrimidin-2-yl)piperidin-4- yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol; N-((2-(4-((S)-4-(4,4-difluorocyclohexyl)-3- ((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-5-hydroxy-7,7-dimethyl-5,6,7,8- tetrahydroquinolin-2-yl)piperidin-1-yl)pyrimidin-5-yl)methyl)-N-methylmethanesulfonamide; (S)-4-(4,4-difluorocyclohexyl)-3-((S)-fluoro(4-(trifluoromethyl)phenyl)methyl)-7,7-dimethyl-2- (1-(5-((1-methylpiperidin-4-yl)oxy)pyrimidin-2-yl)piperidin-4-yl)-5,6,7,8-tetrahydroquinolin-5- ol; (S)-6'-((R)-fluoro(4-(trifluoromethyl)phenyl)methyl)-5'-(4-fluorophenyl)-7'-isopropyl-3',4'- dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-ol; (S)-6'-((R)-fluoro(4- (trifluoromethyl)phenyl)methyl)-5'-(4-fluorophenyl)-7'-isopropyl-3',4'- dihydrospiro[cyclopropane-1,2'-pyrano[2,3-b]pyridin]-4'-ol; 2-phenyl-1-(pyridin-2-yl)-1-(3- (trifluoromethyl)phenyl)ethyl 3,3-dimethylbutanoate; (S)-1-(1-(5-chloropyridin-2-yl)-1-(3- fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-cyclopentylurea; (S)-N-(1-(5-
chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-fluoro-3- (trifluoromethyl)benzamide; 1-((S)-1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2- tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-((R)-3,3-difluorocyclopentyl)urea; (S)-1-(1-(5- chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-(3,3- difluorocyclobutyl)urea; (3'R,9'S)-4'-isopropyl-7',7'-dimethyl-3'-(4-(trifluoromethyl)phenyl)- 6',7',8',9'-tetrahydro-3'H-spiro[cyclopentane-1,1'-furo[3,4-c]quinolin]-9'-ol; (3R,9S)-4-isopropyl- 7,7-dimethyl-3-(4-(trifluoromethyl)phenyl)-2',3',5',6,6',7,8,9-octahydro-3H-spiro[furo[3,4- c]quinoline-1,4'-pyran]-9-ol; (3'R,6'R,9'S)-4'-isopropyl-3'-(4-(trifluoromethyl)phenyl)- 2'',3',3'',5'',6',6'',8',9'-octahydrodispiro[cyclopropane-1,7'-furo[3,4-c]quinoline-1',4''-pyran]-6',9'- diol; (S)-1-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2- phenylethyl)-3-(2,2,2-trifluoroethyl)urea; (R)-3-(((S)-3-(5-chloropyridin-2-yl)-3-(3-fluoro-5- (1,1,2,2-tetrafluoroethoxy)phenyl)-4-phenylbutyl)amino)-1,1,1-trifluoropropan-2-ol; (R)-3-(((R)- 2-(5-chloropyridin-2-yl)-2-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-3- phenylpropyl)amino)-1,1,1-trifluoropropan-2-ol; 5-chloro-6-fluoro-N-(3- (trifluoromethyl)phenethyl)-N-(4-(trimethylsilyl)benzyl)-1H-indole-7-carboxamide; 5-chloro-6- fluoro-N-(3-(trifluoromethoxy)phenethyl)-N-(4-(trimethylsilyl)benzyl)-1H-indole-7- carboxamide; Dacetrapib; N-(4-(tert-butyl)benzyl)-5-chloro-N-(3-(trifluoromethyl)phenethyl)- 1H-pyrrolo[2,3-c]pyridine-7-carboxamide; 3,5-dichloro-N-(4-chlorophenethyl)-N-(4- (perfluoropropan-2-yl)benzyl)benzamide; and N-((5-(tert-butyl)thiophen-2-yl)methyl)-5-chloro- 2-(methylamino)-N-(4-(trifluoromethyl)phenethyl)nicotinamide; and pharmaceutically acceptable salts of the foregoing.
[00105] In some embodiments, the CETP inhibitor is an antibody or peptide. U.S. Pat. No. 5,519,001, herein incorporated by reference, describes a 36 amino acid peptide derived from baboon apo C-1 that inhibits CETP activity. Cho et al. (Biochim. Biophys. Acta (1998) 1391: 133- 144) describes a peptide from hog plasma that inhibits human CETP. Bonin et al. (J. Peptide Res. (1998) 51, 216-225) discloses a decapeptide inhibitor of CETP. A depspeptide fungal metabolite is disclosed as a CETP inhibitor by Hedge et al. in Bioorg. Med. Chem. Lett., (1998) 8:1277-80. An anti-CETP antibody has been described in WO2013075040 A1, herein incorporated by reference.
ADCY Inhibitors
[00106] An ADCY inhibitor can be a small molecule, anti-ADCY antibody, or peptide that inhibits or suppresses adenylate cyclase expression or activity. In some embodiments, the ADCY inhibitor inhibits or suppresses adenylate cyclase expression or activity of one or more of ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 and ADCY10. In some embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9, or ADCY10 inhibitor.
[00107] The following table lists illustrative ADCY inhibitors. These ADCY inhibitors and pharmaceutically acceptable salts thereof are useful in the methods and compositions of the present invention. Each compound’s structure is depicted at the immediate right of its name.
[00108] Additional ADCY inhibitors useful in the compositions and methods of the present invention are disclosed in Dessauer et al. Pharmacol Rev, (2017) 69 (2): 93-139, and have the structure:
and pharmaceutically acceptable salts of the foregoing.
[00109] Additional examples of small molecule ADCY inhibitors include, but are not limited to: SQ22536 (9-(tetrahydro-2-furanyl)-adenine); 2¢,5¢-dideoxyadenosine, 9- cyclopentyladenine; 2¢,5¢-dideoxyadenosine 3¢-diphosphate; 2¢,5¢-dideoxyadenosine 3¢ - monophosphate; MDL-12330A (cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; ; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80;
vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; and pharmaceutically acceptable salts of the foregoing.
[00110] Illustrative ADCY inhibitor peptides useful in the compositions and methods of the present invention include, but are not limited to: adrenocorticotropic hormone; brain natriuretic peptide (BNP); and pituitary adenylate cyclase-activating polypeptide.
Pharmaceutically Acceptable Salts
[00111] Pharmaceutically acceptable salts include, for example, acid-addition salts and base-addition salts. The acid that forms an acid-addition salt can be an organic acid or an inorganic acid. A base that forms a base-addition salt can be an organic base or an inorganic base. In some embodiments, a pharmaceutically acceptable salt is a metal salt. In some embodiments, a pharmaceutically acceptable salt is an ammonium salt.
[00112] Acid-addition salts can arise from the addition of an acid to the free-base form of a compound useful in the compositions and methods of the present invention. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. Non-limiting examples of suitable acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, nicotinic acid, isonicotinic acid, lactic acid, salicylic acid, 4-aminosalicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucaronic acid, saccaric acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, citric acid, oxalic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, glycolic acid, malic acid, cinnamic acid, mandelic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, phenylacetic acid, N- cyclohexylsulfamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, 4- methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- phosphoglyceric acid, 3-phosphoglyceric acid, glucose-6-phosphoric acid, and an amino acid.
[00113] Non-limiting examples of suitable acid-addition salts include a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, a hydrogen phosphate salt, a dihydrogen phosphate salt, a carbonate salt, a bicarbonate salt, a nicotinate salt, an isonicotinate salt, a lactate salt, a salicylate salt, a 4- aminosalicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucaronate salt, a saccarate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a citrate salt, an oxalate salt, a maleate salt, a hydroxymaleate salt, a methylmaleate salt, a glycolate salt, a malate salt, a cinnamate salt, a mandelate salt, a 2-phenoxybenzoate salt, a 2-acetoxybenzoate salt, an embonate salt, a phenylacetate salt, an N-cyclohexylsulfamate salt, a methanesulfonate salt, an ethanesulfonate salt, a benzenesulfonate salt, a p-toluenesulfonate salt, a 2- hydroxyethanesulfonate salt, an ethane-1,2-disulfonate salt, a 4-methylbenzenesulfonate salt, a naphthalene-2-sulfonate salt, a naphthalene-1,5-disulfonate salt, a 2-phosphoglycerate salt, a 3- phosphoglycerate salt, a glucose-6-phosphate salt, and an amino acid salt.
[00114] Metal salts can arise from the addition of an inorganic base to a compound having a carboxyl group. The inorganic base can include a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. Non-limiting examples of suitable metals include lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, and zinc.
[00115] Non-limiting examples of suitable metal salts include a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, and a zinc salt.
[00116] Ammonium salts can arise from the addition of ammonia or an organic amine to a compound having a carboxyl group. Non-limiting examples of suitable organic amines include triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzyl amine, piperazine, pyridine, pyrrazole, imidazole, pyrazine, pipyrazine, ethylenediamine, N,N'-
dibenzylethylene diamine, procaine, chloroprocaine, choline, dicyclohexyl amine, and N- methylglucamine.
[00117] Non-limiting examples of suitable ammonium salts include a triethylammonium salt, a diisopropylammonium salt, an ethanolammonium salt, a diethanolammonium salt, a triethanolammonium salt, a morpholinium salt, an N-methylmorpholinium salt, a piperidinium salt, an N-methylpiperidinium salt, an N-ethylpiperidinium salt, a dibenzylammonium salt, a piperazinium salt, a pyridinium salt, a pyrrazolium salt, an imidazolium salt, a pyrazinium salt, an ethylenediammonium salt, an N,N'-dibenzylethylenediammonium salt, a procaine salt, a chloroprocaine salt, a choline salt, a dicyclohexylammonium salt, and a N-methylglucamine salt.
Methods for Treating or Preventing a Cardiovascular Disorder
[00118] The present invention provides methods for treating or preventing a cardiovascular disorder, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[00119] In certain embodiments, the cardiovascular disorder is acute coronary syndrome (ACS), atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial- hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, cardiovascular disease, coronary heart disease, coronary artery disease, hyperlipidemia, hyperlipidoproteinemia or a vascular complication of diabetes, obesity or endotoxemia.
[00120] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00121] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00122] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'-diphosphate; 2',5'-dideoxyadenosine 3'- monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4- chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro- 5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone, 2-amino-7- phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’- MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP- UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’- ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢- (5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
[00123] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00124] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00125] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00126] Another aspect of the invention provides methods for treating or preventing a cardiovascular disorder, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[00127] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00128] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00129] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00130] The activity level of ADCY can be detected using techniques known in the art. For example, adenylate cyclase assays have been disclosed by Salomon et al., (1974) Analytical Biochemistry, 58(2): 541-548; Wiegn et al., (1993) Anal Biochem. 208(2):217-22; and Storm et al., (1998) Neuron, 20:1199-1210.
[00131] In some embodiments, expression level of ADCY is determined at protein expression level. In some embodiments, protein expression level of ADCY is analyzed using a specific antibody and a protein assay. Any suitable method or assay can be used to measure the level of ADCY protein expression in the biological sample of a subject. Numerous antibody-based detection formats are well known in the art, and include ELISA (enzyme linked immunosorbent assay), radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence assays, immunoprecipitation, protein A assays, immunoelectrophoresis assays, and other related techniques. In some embodiments, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the kits, assays and methods described herein. Antibodies specific for ADCY may be provided in a diagnostic kit that incorporates at least one of these procedures to quantitate ADCY expression. The kit may contain other components, packaging, instructions, or other material to aid the quantitation of the protein and use of the kit.
[00132] Anti-ADCY antibodies as described herein can be obtained commercially or routinely made according to methods such as, but not limited to, inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid encoding such anti- ADCY antibodies. Immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti- ADCY antibodies. Similarly, immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti-ADCY antibodies.
[00133] In other embodiments, level of ADCY is analyzed at the mRNA level. For example, RT-PCR and a pair of specific primers may be used. mRNA are prepared and analyzed according to well-established protocols.
[00134] In certain embodiments, reduced expression or activity level of ADCY in the subject is tissue or cell type specific. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00135] In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
[00136] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[00137] In certain embodiments, the cardiovascular disorder is acute coronary syndrome (ACS), atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial- hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, cardiovascular disease, coronary heart disease, coronary artery disease, hyperlipidemia, hyperlipidoproteinemia or a vascular complication of diabetes, obesity or endotoxemia.
[00138] In certain embodiments, the subject has acute coronary syndrome (ACS).
[00139] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00140] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00141] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00142] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00143] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00144] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00145] The invention further provides methods for treating or preventing a cardiovascular disorder, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00146] The invention further provides methods for treating or preventing a cardiovascular disorder, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00147] The invention further provides methods for treating or preventing a cardiovascular disorder, comprising administering to a subject in need thereof an effective amount of a CETP
inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00148] Methods for determining whether a subject has a particular genotype are well known to a person skilled in the art, see, e.g., WO 2014/154606A1 and WO 2016/016157A1. Methods for Reducing Risk of a Cardiovascular Event
[00149] The present invention further provides methods for reducing risk of a cardiovascular event, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[00150] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00151] The present invention further provides methods for reducing the risk of a cardiovascular event, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[00152] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6,
ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9. Methods to measure the expression or activity level of ADCY are disclosed herein.
[00153] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00154] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00155] In certain embodiments, the cardiovascular event is coronary heart disease, cardiac arrest, myocardial infarction, ischemic stroke, congestive heart failure, sudden cardiac death, cerebral infarction, syncope, transient ischemic attack, angina or coronary revascularization.
[00156] In certain embodiments, the cardiovascular event is an adverse cardiovascular event, e.g., coronary heart disease, death, cardiac arrest, myocardial infarction, ischemic stroke, angina or coronary revascularization. In some embodiments, the cardiac arrest is resuscitated cardiac arrest. In some embodiments, the myocardial infarction is non-fatal myocardial infarction. In some embodiments, the ischemic stroke is non-fatal ischemic stroke. In some embodiments, the angina is unstable angina. In some embodiments, the coronary revascularization is unanticipated coronary revascularization.
[00157] In certain embodiments, the subject has acute coronary syndrome (ACS).
[00158] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00159] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain
embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00160] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00161] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00162] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG,
rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00163] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00164] The invention further provides methods for reducing risk of a cardiovascular event, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19- 4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00165] The invention further provides methods for reducing risk of a cardiovascular event, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19- 4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00166] The invention further provides methods for reducing risk of a cardiovascular event, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19- 4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein
the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. Methods for Treating or Preventing Congestive Heart Failure
[00167] The present invention provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00168] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00169] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00170] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'-diphosphate; 2',5'-dideoxyadenosine 3'- monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4- chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro- 5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone, 2-amino-7- phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone), MANT-ATP;
MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’- MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP- UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’- ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢- (5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
[00171] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00172] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00173] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00174] Another aspect of the invention provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00175] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00176] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00177] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00178] The activity level of ADCY can be detected using techniques known in the art. For example, adenylate cyclase assays have been disclosed by Salomon et al., (1974) Analytical Biochemistry, 58(2): 541-548; Wiegn et al., (1993) Anal Biochem. 208(2):217-22; and Storm et al., (1998) Neuron, 20:1199-1210.
[00179] In some embodiments, expression level of ADCY is determined at protein expression level. In some embodiments, protein expression level of ADCY is analyzed using a specific antibody and a protein assay. Any suitable method or assay can be used to measure the level of ADCY protein expression in the biological sample of a subject. Numerous antibody-based
detection formats are well known in the art, and include ELISA (enzyme linked immunosorbent assay), radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence assays, immunoprecipitation, protein A assays, immunoelectrophoresis assays, and other related techniques. In some embodiments, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the kits, assays and methods described herein. Antibodies specific for ADCY may be provided in a diagnostic kit that incorporates at least one of these procedures to quantitate ADCY expression. The kit may contain other components, packaging, instructions, or other material to aid the quantitation of the protein and use of the kit.
[00180] Anti-ADCY antibodies as described herein can be obtained commercially or routinely made according to methods such as, but not limited to, inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid encoding such anti- ADCY antibodies. Immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti- ADCY antibodies. Similarly, immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti-ADCY antibodies.
[00181] In other embodiments, level of ADCY is analyzed at the mRNA level. For example, RT-PCR and a pair of specific primers may be used. mRNA are prepared and analyzed according to well-established protocols.
[00182] In certain embodiments, reduced expression or activity level of ADCY in the subject is tissue or cell type specific. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00183] In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
[00184] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[00185] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00186] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80;
vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00187] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00188] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00189] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00190] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00191] The invention further provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA,
rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00192] The invention further provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00193] The invention further provides methods for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure. Methods for Reducing Risk of Congestive Heart Failure
[00194] The present invention further provides methods for reducing risk of congestive heart failure, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the congestive heart failure
is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00195] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00196] The present invention further provides methods for reducing the risk of congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00197] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9. Methods to measure the expression or activity level of ADCY are disclosed herein.
[00198] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00199] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00200] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00201] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00202] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00203] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00204] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00205] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00206] The invention further provides methods for reducing risk of congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00207] The invention further provides methods for reducing risk of congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872,
BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
[00208] The invention further provides methods for reducing risk of congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the congestive heart failure is systolic heart failure. In certain embodiments, the congestive heart failure is diastolic heart failure.
Methods for Treating or Preventing Ventricular Systolic Dysfunction
[00209] The present invention provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00210] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00211] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-
17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00212] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'-diphosphate; 2',5'-dideoxyadenosine 3'- monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4- chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro- 5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone, 2-amino-7- phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’- MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP- UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’- ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢- (5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
[00213] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG,
rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00214] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00215] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00216] Another aspect of the invention provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00217] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00218] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00219] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00220] The activity level of ADCY can be detected using techniques known in the art. For example, adenylate cyclase assays have been disclosed by Salomon et al., (1974) Analytical Biochemistry, 58(2): 541-548; Wiegn et al., (1993) Anal Biochem. 208(2):217-22; and Storm et al., (1998) Neuron, 20:1199-1210.
[00221] In some embodiments, expression level of ADCY is determined at protein expression level. In some embodiments, protein expression level of ADCY is analyzed using a specific antibody and a protein assay. Any suitable method or assay can be used to measure the level of ADCY protein expression in the biological sample of a subject. Numerous antibody-based detection formats are well known in the art, and include ELISA (enzyme linked immunosorbent assay), radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence assays, immunoprecipitation, protein A assays, immunoelectrophoresis assays, and other related techniques. In some embodiments, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the kits, assays and methods described herein. Antibodies specific for ADCY may be provided in a diagnostic kit that incorporates at least one of these procedures to quantitate ADCY expression. The kit may contain other components, packaging, instructions, or other material to aid the quantitation of the protein and use of the kit.
[00222] Anti-ADCY antibodies as described herein can be obtained commercially or routinely made according to methods such as, but not limited to, inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid
encoding such anti- ADCY antibodies. Immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti- ADCY antibodies. Similarly, immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti-ADCY antibodies.
[00223] In other embodiments, level of ADCY is analyzed at the mRNA level. For example, RT-PCR and a pair of specific primers may be used. mRNA are prepared and analyzed according to well-established protocols.
[00224] In certain embodiments, reduced expression or activity level of ADCY in the subject is tissue or cell type specific. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00225] In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
[00226] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[00227] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00228] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain
embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00229] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00230] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00231] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG,
rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00232] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00233] The invention further provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00234] The invention further provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the
ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00235] The invention further provides methods for treating or preventing ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00236] Methods for determining whether a subject has a particular genotype are well known to a person skilled in the art, see, e.g., WO 2014/154606A1 and WO 2016/016157A1.
Methods for Reducing Risk of Ventricular Systolic Dysfunction
[00237] The present invention further provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00238] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00239] The present invention further provides methods for reducing the risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of
ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00240] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9. Methods to measure the expression or activity level of ADCY are disclosed herein.
[00241] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00242] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00243] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00244] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢-
dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00245] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00246] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00247] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA,
rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00248] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00249] The invention further provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00250] The invention further provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
[00251] The invention further provides methods for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the ventricular systolic dysfunction is left ventricular systolic dysfunction. In certain embodiments, the ventricular systolic dysfunction is right ventricular systolic dysfunction.
Methods for Treating or Preventing Ventricular Diastolic Dysfunction
[00252] The present invention provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00253] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00254] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00255] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'-diphosphate; 2',5'-dideoxyadenosine 3'-
monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4- chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro- 5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone, 2-amino-7- phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’- MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP- UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’- ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢- (5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
[00256] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00257] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00258] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00259] Another aspect of the invention provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00260] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00261] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00262] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00263] The activity level of ADCY can be detected using techniques known in the art. For example, adenylate cyclase assays have been disclosed by Salomon et al., (1974) Analytical
Biochemistry, 58(2): 541-548; Wiegn et al., (1993) Anal Biochem. 208(2):217-22; and Storm et al., (1998) Neuron, 20:1199-1210.
[00264] In some embodiments, expression level of ADCY is determined at protein expression level. In some embodiments, protein expression level of ADCY is analyzed using a specific antibody and a protein assay. Any suitable method or assay can be used to measure the level of ADCY protein expression in the biological sample of a subject. Numerous antibody-based detection formats are well known in the art, and include ELISA (enzyme linked immunosorbent assay), radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence assays, immunoprecipitation, protein A assays, immunoelectrophoresis assays, and other related techniques. In some embodiments, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the kits, assays and methods described herein. Antibodies specific for ADCY may be provided in a diagnostic kit that incorporates at least one of these procedures to quantitate ADCY expression. The kit may contain other components, packaging, instructions, or other material to aid the quantitation of the protein and use of the kit.
[00265] Anti-ADCY antibodies as described herein can be obtained commercially or routinely made according to methods such as, but not limited to, inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid encoding such anti- ADCY antibodies. Immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti- ADCY antibodies. Similarly, immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti-ADCY antibodies.
[00266] In other embodiments, level of ADCY is analyzed at the mRNA level. For example, RT-PCR and a pair of specific primers may be used. mRNA are prepared and analyzed according to well-established protocols.
[00267] In certain embodiments, reduced expression or activity level of ADCY in the subject is tissue or cell type specific. In some embodiments, the subject is known to have reduced
expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00268] In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
[00269] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[00270] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00271] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS;
MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00272] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00273] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00274] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00275] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00276] The invention further provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount
of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00277] The invention further provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00278] The invention further provides methods for treating or preventing ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the ventricular diastolic dysfunction
is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00279] Methods for determining whether a subject has a particular genotype are well known to a person skilled in the art, see, e.g., WO 2014/154606A1 and WO 2016/016157A1.
Methods for Reducing Risk of Ventricular Diastolic Dysfunction
[00280] The present invention further provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00281] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00282] The present invention further provides methods for reducing the risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00283] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6,
ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9. Methods to measure the expression or activity level of ADCY are disclosed herein.
[00284] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00285] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00286] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00287] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-
GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00288] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00289] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00290] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00291] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00292] The invention further provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and
wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00293] The invention further provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
[00294] The invention further provides methods for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. In certain embodiments, the ventricular diastolic dysfunction is left ventricular diastolic dysfunction. In certain embodiments, the ventricular diastolic dysfunction is right ventricular diastolic dysfunction.
Methods for Treating or Preventing Heart Failure with Preserved Ejection Fraction
[00295] The present invention provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[00296] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00297] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00298] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'-diphosphate; 2',5'-dideoxyadenosine 3'- monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4- chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro- 5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone, 2-amino-7- phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’- MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP- UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP;
Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’- ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢- (5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
[00299] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00300] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00301] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00302] Another aspect of the invention provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[00303] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00304] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00305] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00306] The activity level of ADCY can be detected using techniques known in the art. For example, adenylate cyclase assays have been disclosed by Salomon et al., (1974) Analytical Biochemistry, 58(2): 541-548; Wiegn et al., (1993) Anal Biochem. 208(2):217-22; and Storm et al., (1998) Neuron, 20:1199-1210.
[00307] In some embodiments, expression level of ADCY is determined at protein expression level. In some embodiments, protein expression level of ADCY is analyzed using a specific antibody and a protein assay. Any suitable method or assay can be used to measure the level of ADCY protein expression in the biological sample of a subject. Numerous antibody-based detection formats are well known in the art, and include ELISA (enzyme linked immunosorbent assay), radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence assays, immunoprecipitation, protein A assays, immunoelectrophoresis assays, and other related techniques. In some embodiments, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay
and are within the scope of the kits, assays and methods described herein. Antibodies specific for ADCY may be provided in a diagnostic kit that incorporates at least one of these procedures to quantitate ADCY expression. The kit may contain other components, packaging, instructions, or other material to aid the quantitation of the protein and use of the kit.
[00308] Anti-ADCY antibodies as described herein can be obtained commercially or routinely made according to methods such as, but not limited to, inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid encoding such anti- ADCY antibodies. Immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti- ADCY antibodies. Similarly, immunization of an animal using purified recombinant ADCY or peptide fragments thereof, is an example of a method of preparing anti-ADCY antibodies.
[00309] In other embodiments, level of ADCY is analyzed at the mRNA level. For example, RT-PCR and a pair of specific primers may be used. mRNA are prepared and analyzed according to well-established protocols.
[00310] In certain embodiments, reduced expression or activity level of ADCY in the subject is tissue or cell type specific. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9.
[00311] In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level. In some embodiments, the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
[00312] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human.
[00313] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00314] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00315] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00316] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00317] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00318] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00319] The invention further provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00320] The invention further provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of
any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00321] The invention further provides methods for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00322] Methods for determining whether a subject has a particular genotype are well known to a person skilled in the art, see, e.g., WO 2014/154606A1 and WO 2016/016157A1.
Methods for Reducing Risk of Heart Failure with Preserved Ejection Fraction
[00323] The present invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of: a) a CETP inhibitor; and b) an ADCY inhibitor.
[00324] In certain embodiments, administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition.
[00325] The present invention further provides methods for reducing the risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity
level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor.
[00326] In certain embodiments, the control level is an expression or activity level of ADCY established based on the expression or activity level of ADCY of subjects who do not respond positively to treatment of a CETP inhibitor in the absence of an ADCY inhibitor. In certain embodiments, reduced expression or activity level of ADCY in the subject compared to a control level is caused by one or more polymorphisms or mutations in the ADCY gene of the subject. In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10. In some embodiments, the ADCY is ADCY9. Methods to measure the expression or activity level of ADCY are disclosed herein.
[00327] In some embodiments, the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH- 03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00328] In some embodiments, the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00329] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
[00330] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor. In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)-adenine), 2¢,5¢- dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢- dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)-
quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00331] In some embodiments, the ADCY inhibitor is adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide.
[00332] In certain embodiments, the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00333] In certain embodiments, the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00334] In certain embodiments, the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
[00335] The invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG. In some embodiments, the subject is known to have genotype rs1967309/AA.
[00336] The invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC, rs12920508/CG, rs2531971/AC, or rs12599911/GT. In some embodiments, the subject is known to have genotype rs1967309/AG.
[00337] The invention further provides methods for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the CEPT inhibitor is BMS795311, CP-800,569, JNJ- 28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing and wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA,
rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG, rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT. Dosages
[00338] The dosage of the CETP inhibitors and ADCY inhibitors of the methods and compositions of the invention can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the disorder to be treated or prevented; the severity of the cardiovascular event; the route of administration; the renal or hepatic function of the subject; or the CETP or ADCY inhibitor to be administered.
[00339] In some embodiments, the daily dosage amount of CETP inhibitor useful in the methods and compositions of the present invention ranges from about 1 mg to about 1000 mg.
[00340] In some embodiments, the daily dosage amount of ADCY inhibitor useful in the methods and compositions of the present invention ranges from about 1 mg to about 1000 mg.
[00341] In certain embodiments, the CETP inhibitor is dalcetrapib or a pharmaceutically acceptable salt thereof, wherein dalcetrapib or pharmaceutically acceptable salt thereof is administered orally at a dose of about 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg daily.
[00342] In certain embodiments, the CETP inhibitor is torcetrapib or a pharmaceutically acceptable salt thereof, wherein torcetrapib or pharmaceutically acceptable salt thereof is administered orally at a dose of about 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg daily.
[00343] In certain embodiments, the CETP inhibitor is anacetrapib or a pharmaceutically acceptable salt thereof, wherein anacetrapib or pharmaceutically acceptable salt thereof is administered orally at a dose of about 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, or 200 mg daily.
[00344] In certain embodiments, the CETP inhibitor is evacetrapib a pharmaceutically acceptable salt thereof, wherein evacetrapib or pharmaceutically acceptable salt thereof is
administered orally at a dose of about 30 mg, 60 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg daily.
[00345] In certain embodiments, the CETP inhibitor is BAY 60-5521 or a pharmaceutically acceptable salt thereof, wherein BAY 60-5521 or pharmaceutically acceptable salt thereof is administered orally at a dose of about 5 mg, 12.5 mg, 25 mg, 30mg, 40mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg daily.
[00346] In some embodiments, the subject of the forgoing methods is a human. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric human. Compositions and Kits
[00347] The present invention also provides compositions comprising a) an effective amount of a CETP inhibitor and an ADCY inhibitor; and b) a pharmaceutically acceptable carrier or vehicle.
[00348] In certain embodiments, the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ- 28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
[00349] In certain embodiments, the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
[00350] In certain embodiments, the ADCY inhibitor is SQ22536 (9-(tetrahydro-2-furanyl)- adenine), 2¢,5¢-dideoxyadenosine, 9-cyclopentyladenine, 2¢,5¢-dideoxyadenosine 3¢-diphosphate, 2¢,5¢-dideoxyadenosine 3¢ -monophosphate, MDL-12330A (cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine), compounds such as 7,8-dihydro-5(6H)- quinazolinone derivatives disclosed in JP Patent Application No. 2001-153954 (preferably, 2- amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone, 2-amino-7-(4-methoxyphenyl)-7,8- dihydro-5(6H)-quinazolinone, 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone, 4.2-amino-7- (2-furanyl)-7,8-dihydro-5(6H)-quinazolinone, and 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)- quinazolinone), MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT- UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS;
MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT- ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP- GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT- IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT- ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H- Benzo[d]imidazol-2-ylthio)-N¢-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; or a pharmaceutically acceptable salt of any of the foregoing.
[00351] In certain embodiments, the pharmaceutical acceptable carrier or vehicle can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the CETP inhibitor or ADCY inhibitor is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents.
[00352] The compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained release formulation; (3) topical application, for example, as a cream, ointment, or a controlled release
patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.
[00353] Compositions of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, e.g., from about 5 percent to about 70 percent, or from about 10 percent to about 30 percent.
[00354] In certain embodiments, a composition of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a CETP inhibitor or ADCY inhibitor. In certain embodiments, an aforementioned composition renders orally bioavailable a CETP inhibitor or ADCY inhibitor.
[00355] Methods of preparing these compositions or compositions include the step of bringing into association a CETP inhibitor or ADCY inhibitor with the carrier and, optionally, one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association a CETP inhibitor or ADCY inhibitor with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[00356] Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a CETP inhibitor or ADCY inhibitor as
an active ingredient. A CETP inhibitor or ADCY inhibitormay also be administered as a bolus, electuary or paste.
[00357] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non- ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[00358] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[00359] The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled
release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[00360] Liquid dosage forms for oral administration of the CETP inhibitor or ADCY inhibitor include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[00361] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[00362] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[00363] Compositions of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by admixing one or both of the CETP inhibitor and ADCY inhibitor with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository
wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[00364] Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray compositions containing such carriers as are known in the art to be appropriate.
[00365] Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically- acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
[00366] The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[00367] Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[00368] Transdermal patches have the added advantage of providing controlled delivery of a CETP inhibitor or ADCY inhibitor to a subject. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
[00369] Pharmaceutical compositions of this invention suitable for parenteral administration can comprise a CETP inhibitor, an ADCY inhibitor and one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers,
bacteriostats, solutes which render the composition isotonic with the blood of the intended recipient or suspending or thickening agents.
[00370] Examples of suitable aqueous and nonaqueous carriers which may be employed in the compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[00371] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[00372] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally- administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[00373] Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable compositions are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
[00374] When the CETP inhibitor or ADCY inhibitor is administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing,
for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[00375] The preparations of the present invention may be administered orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
[00376] The phrases“parenteral administration” and“administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[00377] The phrases“systemic administration,”“administered systemically,”“peripheral administration” and“administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
[00378] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
[00379] Regardless of the route of administration selected, the CETP inhibitor or ADCY inhibitor, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
[00380] Actual dosage levels of the active ingredients in the compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the
desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[00381] The selected dosage level will depend upon a variety of factors including the activity of the particular CETP inhibitor or ADCY inhibitor employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[00382] A physician or veterinarian can readily determine and prescribe the effective amount of the pharmaceutical composition. For example, the physician or veterinarian could start doses of the CETP inhibitor or ADCY inhibitor employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[00383] In some embodiments, a suitable daily dose of a CETP inhibitor or an ADCY inhibitor is that amount of the CETP inhibitor or ADCY inhibitor which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
[00384] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms, e.g., one administration per day.
[00385] The invention also provides kits useful for treating or preventing a cardiovascular disorder or reducing risk of a cardiovascular event, as described herein. In some embodiments, the kits comprise a CETP inhibitor or an ADCY inhibitor and instructions for its use. In some embodiments, each of the CETP inhibitor and ADCY inhibitor is present in a separate composition. In some embodiments, the CETP inhibitor and ADCY inhibitor are present in the same composition. The invention also provides a CETP inhibitor and an ADCY inhibitor as described herein and compositions comprising an effective amount of a CETP inhibitor and an ADCY inhibitor as described herein for use in the methods described herein.
Examples
Example 1: Generation of Adyc9 gene-trapped mice
[00386] Adyc9 gene-trapped (Adcy9Gt/Gt) mice were generated initially from Lexicon Pharmaceuticals (Zambrowicz et al., Proc Natl Acad Sci U S A. (2003)100:14109-14). Cryo- preserved sperm from the B6;129S5-Adcy9Gt(neo)159Lex/Mmucd strain was imported from the Mutant Mouse Regional Resource Center (MMRRC) and used for in vitro fertilization and oviduct transfer at the Institute for Research in Immunology and Cancer (IRIC) animal facility in a specific-pathogen-free area and their breeding and reproduction was approved by the University de Montréal Deontology Committee on Animal Experimentation. MaxBax accelerated backcrossing and genotyping (Charles River, Sherbrooke, Canada) was performed to achieve >98.6% C57BL/6J genetic background. Procedures involving mice were performed at the Montreal Heart Institute (MHI) Research Center and approved by the local ethics committee for animal research in accordance with the Canadian Council on Animal Care guidelines. Adcy9Gt/Gt mice were bred by mating Adcy9WT/Gt animals. Mice hemizygous for transgenic human CETP minigene (CETPWT) were obtained from Jackson laboratory (Bar Harbor, ME) and were on 100% C57BL/6J genetic background. To obtain mice that were transgenic for CETP and with homozygous inactivation for Adcy9 (CETPGt), CETPWT mice were first crossed with Adcy9WT/Gt animals, then mice transgenic for CETP and heterozygote for Adcy9WT/Gt were crossed with Adcy9Gt/Gt or Adcy9WT/Gt animals. All mice were under a C57BL/6J background, males and aged from 8 to 12 weeks. Blood collection was performed after 4 hours of fasting. Example 2: Atherosclerosis model
[00387] Wild-type (WT) and Adcy9Gt/Gt male mice (8 to 12-week-old) were injected with a single dose of an AAV8 viral vector expressing gain-of-function Pcsk9D377Y (AAV8-Pcsk9D377Y, 6.5x1011 gene copies) as previously described. (Roche-Molina et al., Arterioscler Thromb Vasc Biol. (2015) 35:50-59) A control group was injected with a saline solution in preliminary experiments to confirm the effect of the AAV8-Pcsk9D377Y infection on LDL receptor expression. Starting one week after AAV8-Pcsk9D377Y injection, mice were fed for 16 weeks with a chow- based (Purina 5015) atherogenic diet (TD, 150545, Envigo, Madison, WI) enriched with 0.75% cholesterol and having the following caloric composition: proteins 20.4%, carbohydrates 42.7%
and fats 36.9% (3.9 kcal/g). Food and water were available ad libitum. After the sacrifice, atherosclerosis development was investigated in the whole aorta, aortic root and brachiocephalic artery by an experienced observer blinded to the mouse genotype. Example 3: Adcy9 inactivation protects against atherosclerosis
[00388] Quantification of Adcy9 mRNA expression by reverse transcription-quantitative PCR (RT-qPCR)
[00389] Mice total RNA were extracted from heart ventricles using RNeasy isolation kit (QIAGEN, Toronto, ON, Canada) with DNase I procedure according to the manufacturer’s protocol. cDNA was synthesized with components from High-Capacity cDNA Reverse transcription Kits without inhibitor (Applied Biosystems #4368814, Foster City, CA) and with the use of MultiScribeTM Reverse Transcriptase, according to the manufacturer’s procedures. RNA quantification and quality were assessed using Agilent RNA 6000 Nano Kit for Bioanalyzer 2100 System (Agilent Technologies, Santa Clara, CA). Primers for Adcy9 were designed using the Beacon designer software v.8 (Premier Biosoft) and obtained from IDT (Coralville, IA). Gapdh was used as the reference gene for normalization. The quantitative PCR (qPCR) was performed with SYBR-Green reaction mix (BioRad, Hercules, CA). The qPCR conditions consisted of an initial denaturation at 95°C for 3 minutes followed with 40 cycles of amplification, each cycle consisting of 95°C for 10 seconds and 60°C for 30 seconds.
[00390] The effect of the Adcy9Gt modified target locus on Adcy9 expression in Adcy9Gt/Gt mice was characterized. Using RT-qPCR, it was demonstrated that Adcy9 mRNA expression in the heart was decreased by 50% in Adcy9WT/Gt mice and by at least 90% in Adcy9Gt/Gt mice compared to WT (FIG.1A). In the skeletal muscle, where the ADCY9 gene has been reported to be highly expressed, it was observed that protein expression was abolished in Adcy9Gt/Gt mice compared to WT (FIG.1E). Then, WT and Adcy9Gt/Gt mice were infected with AAV8-Pcsk9D377Y to induce hypercholesterolemia. One week after infection and before the start of the atherogenic diet, plasma PCSK9 concentration was dramatically increased from 0.1 µg/mL to 17.9±3.5 µg/mL in WT and 26.6±7.5 µg/mL in Adcy9Gt/Gt mice. PCSK9 concentrations increased to 71.0±19.1 µg/mL in WT and 90.8±20.1 µg/mL in Adcy9Gt/Gt mice, after 8 weeks of atherogenic diet, where
they stayed almost stable at 12 weeks (FIG. 1B). PCSK9D377Y induced a reduction of 90% in hepatic LDL receptor expression that was similar in WT and Adcy9Gt/Gt (FIG.1C).
[00391] Determination of plasma cholesterol concentration, lipoprotein profile and plasma PCSK9
[00392] Blood samples were collected in EDTA-coated tubes and plasma was separated by centrifugation (2000 x g, 10 minutes) and conserved at -80°C until analysis. Total cholesterol was quantified by colorimetric enzymatic assay (Wako Diagnostics, 999-02601, Richmond, VA) and measured at 600 nm in 96-well black microplates with flat bottom according to a micro-method used in our laboratory. To determine the lipoprotein profile, blood samples were pooled from 5 mice per group and a fast protein liquid chromatography (FPLC) size fractionation on Sepharose was performed by a specialized lipidomics core facility (University of Alberta, Edmonton, AB). PCSK9 concentration in plasma was determined using an ELISA kit targeting mouse PCSK9 (Cyclex Co, #CY-8078, Japan).
[00393] Plasma cholesterol levels rose from 3.8±0.3 mM in WT and 4.9±0.2 mM in Adcy9Gt/Gt to 44.5±6.7 mM and 42.4±5.1 mM (P=NS) at 16 weeks (FIG. 1D). Visualization of lipoprotein profile by chromatography showed that WT and Adcy9Gt/Gt mice had a similar profile rich in HDL at baseline. PCSK9D377Y and the hypercholesterolemic diet induced an atherogenic redistribution of cholesterol out of HDL particles and into VLDL and LDL particles in both types of mice (FIG.2A and FIG.2B).
[00394] En face quantification of aortic atherosclerotic lesions
[00395] Atherosclerosis lesions were quantified on whole aorta dissected en face. Aortas were fixed in 4% paraformaldehyde (PFA) overnight and then stained with a 0.7% solution of Oil Red O (Sigma-Aldrich) for 1 hour and then counterstained with Nuclear Fast Green at 0.05% (Sigma-Aldrich, F7258) to optimize contrast. Images were captured using a Leica Microsystem (Concord, ON, Canada) stereomicroscope with digital camera (MC170 HD, Leica Microsystem). Atherosclerotic lesions were quantified from the aortic root down to the iliac artery bifurcation using Image-Pro Premier 9.2 (Media Cybernetics, Inc, Rockville, MD). Percent atherosclerotic lesion area was expressed as the percentage of the intima area presenting Oil Red O staining.
[00396] Atherosclerotic lesion cross-sectional quantification in the aortic root
[00397] The base of the heart was embedded in OCT compound and sliced in 10 µm sections before fixation with 10% cold formalin for five minutes and then rinsed twice with deionized water. Slides were immersed twice in 100% propylene glycol for five minutes. Aortic roots were stained with a 0.7% Oil Red O solution for 48 hours at room temperature. Afterwards, slides were successively immersed in 100% propylene glycol, 85% propylene glycol solution and deionized water baths, using agitation. Slides were counterstained with a hematoxylin solution for a few seconds, rinsed and then mounted using an aqueous medium. Atherosclerosis lesions were quantified at regular distances from the base of the aortic sinuses to 500 µm more distally in the aortic root. Images were obtained by microscope and quantified by Image-Pro Premier 9.2.
[00398] Atherosclerotic lesion quantification in the brachiocephalic artery
[00399] The presence of plaques, fibrin, red blood cells and break in the plaque cap was determined in the brachiocephalic artery. All solutions used for staining were from EMS (Hatfield, PA) except for phosphotungstic acid that was from Sigma-Aldrich. Six micrometer-thick sections (6 µm), taken from paraffin-embedded brachiocephalic artery, were stained according to the Carstairs’ method with modification as described previously12. After rehydration, sections were incubated in 5% ferric ammonium sulfate solution for 5 minutes and rinsed with tap water. Sections were then stained with Mayer hematoxylin solution for 5 minutes and rinsed with tap water. Additional stainings were performed with picric acid orange G for 1 hour and Ponceau-fuchsin for 5 minutes before rinsing with distilled water for each staining. Muscle tissue was differentiated from other structures with 1% phosphotungstic acid for 3 minutes before rinsing with distilled water. Final staining for collagen was performed with Anilin Blue (2.5%, 2 minutes) before dehydration clearing with xylene and mounting in Permount (Thermo Fisher Scientific, Toronto, ON, Canada). The sections were scored for presence of plaques, fibrin deposition at the surface of and in the plaque, and breaks in the plaque cap. To be scored positively, a mouse needed to show the feature of interest in two sections separated by 48 µm. Plaque size was scored according to the percentage of cross-sectional area occupied by plaque (scores of 0: <50%, 1: 50-75%, and 2: >75%).
[00400] At sacrifice, aortas showed 11.3±2.1% of the surface of the intima covered with atherosclerotic lesions in WT mice compared to 3.8±0.6% in Adcy9Gt/Gt mice (P<0.01, FIG. 3A and FIG.3D), a reduction of 65%. Cross-sectional quantification showed a numerical reduction of
plaque area all along the aortic root by Adcy9 inactivation (p=0.07 at 500 µm, FIG. 3B and FIG. 3E). Brachiocephalic arteries are the site in mice where plaques are more complex and prone to rupture (Rosenfeld et al., Arterioscler Thromb Vasc Biol. (2000) 20:2587-92); FIG.3C shows that all WT animals had plaques in the brachiocephalic arteries in contrast to Adcy9Gt/Gt mice (100%, versus 50%, P<0.05). The plaques in WT mice were also larger and presented more frequently fibrin deposits at their surface (P<0.05) and cap ruptures compared to Adcy9Gt/Gt mice (FIG.3F). Example 4: Adcy9 inactivation reduces CD68-positive macrophage (foam cell) accumulation and their proliferation in atherosclerotic lesions
[00401] Immunofluorescent detection of CD68-positive macrophages (foam cells) and their proliferation in the aortic root (FIG.4A and FIG.4D)
[00402] The base of the heart was embedded in OCT compound and 10 µm sections were cut with a cryostat. Slides were incubated in PBS to remove the OCT and then immersed in 4% PFA (pH 7.4) for 20 minutes. After fixation, slides were washed in PBS. Permeabilization, blocking and antibody incubation were performed in a Tris solution (in mM): Tris-base 50, NaCl 150, BSA 1%, Triton X-100 0.4% and fetal bovine serum 20% at pH 7.4. Rat antibody against CD68 was diluted 1/200 (BioRad, #MCA19557) and rabbit antibody against Ki67 was used at 1 µg/mL (Abcam, #ab15580). For determination of CD68-positive cell accumulation in the atherosclerotic lesions, CD68 was visualized using goat anti-rat antibody labeled with Alexa-647 (Thermo Fisher Scientific, # cat A-21247). For co-staining with Ki67, CD68 was visualized with goat anti-rat antibody labeled with Alexa-568 (Thermo Fisher Scientific, #A11077) and Ki67 was visualized with a goat anti-rabbit antibody labeled with Alexa-647 (Thermo Fisher Scientific, #A- 27040). The nuclei were counterstained with DAPI. Images were acquired with a confocal microscope (LSM 710, Zeiss, Peabody, CA). Imaging quantifications were performed with Image- Pro Premier 9.2 from three sections of the aortic root. Accumulation of CD68-positive foam cells was quantified as percent of the total lesion area from three aortic root sections. Cells were considered positive for Ki67 if the staining colocalized with DAPI. To evaluate proliferation of CD68-positive foam cells, double positive Ki67/CD68 cells were counted.
[00403] CD68-positive foam cells, a key constituent of atherosclerotic plaques, represented 19.0±1.9% and 11.4±2.1% of the lesion area in WT and Adcy9Gt/Gt mice, respectively (P<0.05, FIG.4A).
[00404] In situ hybridization showed Adcy9 expression in atherosclerotic lesions at sites of foam cell accumulation (FIG. 4B). In situ hybridization was performed according to the manufacturer’s recommended procedure (Advanced Cell diagnostic, Hayward, CA). Staining was performed on 6 µm-thick sections of paraffin-embedded femoral artery or aortic root. Sections were counterstained with hematoxylin. It was observed that the signal for Adcy9 was specific by comparing tissue sections from Adcy9Gt/Gt and WT mice (data not shown). Adcy9 probe was Mm- Adcy9 targeting nucleotides 1522-2502 of NM_009624.3. Probe for the bacterial gene dapB was used as a negative control.
[00405] Immunofluorescence detection of Ki67 revealed that proliferation of CD68- positive foam cells was significantly decreased in Adcy9Gt/Gt compared to WT (P<0.05, FIG.4C and FIG.4E). Example 5: Adcy9 inactivation potentiates endothelial function
[00406] Endothelial-dependent vasodilatation to ACh in untreated animals (no AAV8- Pcsk9D377Y and no atherogenic diet) was potentiated in the femoral arteries of Adcy9Gt/Gt mice compared to WT (P<0.01, FIG.5A); in contrast, endothelial-independent vasodilation to the nitric oxide donor SNP was similar in both groups (FIG. 5E). Adcy9 inactivation also potentiated endothelial-dependent vasodilatation in response to increased shear stress (15 dynes/cm2) compared to WT (42.3±7.1% versus 28.2±6.3%, P=0.08, FIG. 5B). There was no difference detected between untreated mice (no AAV8-Pcsk9D377Y and no atherogenic diet) when the aorta was evaluated. In femoral arteries from atherosclerotic animals (AAV8-Pcsk9D377Y and atherogenic diet) both endothelial-dependent (ACh-induced) and endothelial-independent vasodilatation were increased in Adcy9Gt/Gt mice compared to WT (P<0.05, FIG.5C and FIG.5F). This suggests that sensitivity of vascular smooth muscle cells to NO might be increased by Adcy9 inactivation. Similar benefits were observed in the aorta of animals treated with the AAV8- Pcsk9D377Y and atherogenic diet when comparing Adcy9Gt/Gt to WT mice (FIG.5D and FIG.5G).
[00407] Selective pharmacological blockade of the signaling pathways responsible for endothelial-dependent vasodilatation (Vanhoutte et al., Acta Physiol (Oxf). (2017) 219:22-96) was then used to identify the mechanism responsible for the improvement observed in Adcy9Gt/Gt mice. The nitric oxide synthase blocker L-NNA inhibited significantly ACh-induced vasodilatation both in WT and Adcy9Gt/Gt mice (P<0.01), but flow-mediated vasodilatation was numerically reduced only in Adcy9Gt/Gt mice (FIG. 6A and FIG. 6D). In contrast, the cyclooxygenase (responsible for production of prostacyclin) blocker meclofenamate or the cocktail of endothelial-dependent hyperpolarization blockers (TRAM-34 and apamin), inhibited ACh-induced endothelial- dependent vasodilatation in Adcy9Gt/Gt mice (P<0.01 for both pathways, FIG.6B and FIG.6E) but not in WT mice. Overall, these pharmacological results demonstrate that the effect of Adcy9 inactivation on endothelial function is dependent on all three endothelial cell signaling pathways.
[00408] Adcy9Gt/Gt mice are systemically inactivated for Adcy9 making it difficult to identify its role in vascular tissue that could be associated with the observed potentiated endothelial function. Therefore, Adcy9 mRNA expression was studied by in situ hybridization on histological sections and was demonstrated in the femoral artery wall. Specificity of the Adcy9 mRNA signal was confirmed by absence of dots with the negative control probe (FIG.6C).
Example 6: Adcy9 inactivation increases body weight and adipose tissue volume
[00409] Body weight was measured every week from the week of infection with AAV8- Pcsk9D377Y and for a total of 16 weeks. Feed efficiency, the ratio of the weight gain to the caloric intake (g/100kcal), was calculated for a total of 8 weeks during the atherogenic diet.
[00410] Adcy9Gt/Gt mice gained more weight than WT animals during the 16 weeks of atherogenic diet, to reach weights of 45.1±2.4 g and 33.5±1.2 g respectively (P<0.01, FIG. 7A). MRI performed at week 14 showed that Adcy9Gt/Gt mice presented more adipose tissue than WT (FIG.7B), with a doubling of total body adipose tissue volume in Adcy9Gt/Gt mice (9.4±1.2 cm3) compared to WT (4.3±0.4 cm3, P<0.01, FIG. 7C). This increase was confirmed by the larger inguinal, perirenal, epididymal and interscapular fat depots (FIG. 7D). Histological sections showed that Adcy9 inactivation resulted in hypertrophic adipocytes in epididymal white adipose tissue and larger lipid droplets in interscapular brown adipose tissue (FIG. 7E and FIG. 7F). No significant change in blood glucose or insulin concentrations was observed in response to the
atherogenic diet and increased fat deposits, suggesting that the weight gain in response to Adcy9 inactivation does not modify insulin sensitivity (data not shown). Example 7: Adcy9 inactivation modulates autonomic nervous system activity
[00411] Telemetry for ECG recording
[00412] Telemetry was used to monitor and record ECG in conscious free moving unanesthetized WT and Adcy9Gt/Gt mice. Mice were equipped with an ECG transmitter (ETA-F10, DSI, St Paul, MN) for mice and electrodes were placed subcutaneously on the abdomen in a conventional lead II position (Brouillette et al., J Mol Cell Cardiol. (2007) 43:159-67). Recordings were performed continuously at 1 KHz per channel with IOX (version 2.8.0.17, EMKA Inc) 10 days post-surgery. ECGs were analyzed for heart rate variability (HRV) according to the guide by Thireau et al. (Exp Physiol. (2008) 93:83-94), and with the software ECG Auto (version v3.3.0.25, EMKA Inc). Periods containing 1500 beats for day time (6 AM to 6 PM) and night time (6 PM to 6 AM) were analyzed. Data were analyzed to extract the time domain parameters RR interval and pNN(6), the latter representing the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity.
[00413] Given the differences in weight gain between Adcy9Gt/Gt and WT mice, feed efficiency defined as the ratio of weight gain over energy intake was evaluated over the same period of time. With the atherogenic diet, Adcy9Gt/Gt mice showed a significant increase in feed efficiency (1.2±0.1 g/100 kCal) compared to WT (0.6±0.1 g/100 kCal, P<0.01, FIG. 8A). This indicates that the control of energetic balance, which is dependent on the autonomic nervous system, is modified by Adcy9 inactivation. Therefore, autonomic nervous system activity was evaluated by measuring heart rate variability by telemetry in WT and Adcy9Gt/Gt mice. The RR interval was increased in Adcy9Gt/Gt mice (135±5 ms) compared to WT mice (123±4 ms, P=0.05, FIG.8B). Nocturnal heart rate was lower in Adcy9Gt/Gt mice (447±10 bpm) compared to WT mice (475±10 bpm, P=0.06). pNN(6), which represents the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity17, was increased during the night period in Adcy9Gt/Gt mice (21.6±2.4%) compared to WT (14.5±2.2%, P<0.05, FIG.8C). Example 8: Adcy9 inactivation-induced atheroprotection is lost in mice expressing CETP.
[00414] In order to study the interactions between Adcy9 and CETP expression, transgenic mice for the human CETP minigene (CETPWT) were crossed with Adcy9Gt/Gt mice to obtain animals with CETP and inactivated for Adcy9 (CETPGt). Both types of mice (CETPWT and CETPGt) were then subjected to the previously described atherogenic protocol (involving AAV8- Pcsk9D377Y injection and atherogenic diet). CETPWT and CETPGt mice developed similar atherosclerotic lesions that covered 11.8±1.8% and 8.6±1.9% of the intima area, respectively (P=NS, FIG.9A and FIG.9C). FIG.9B compares percentage of lesion area in the whole aorta in WT, Adcy9Gt/Gt, CETPWT and CETPGt to emphasize the absence of atheroprotection in CETPGt mice compared to Adcy9Gt/Gt mice (P<0.05). These results indicate that Adcy9 does not significantly affect atherosclerosis development in presence of CETP. Example 9: Adcy9 inactivation-induced endothelial function protection is lost in mice expressing CETP
[00415] Given the loss of Adcy9 inactivation-induced atheroprotection when the CETP gene is introduced, vasodilatation to ACh and SNP in femoral arteries from atherosclerotic CETPWT and CETPGt (FIG. 10A and FIG. 10B) were studied. Adcy9 inactivation no longer modified endothelial-dependent vasodilatation in response to ACh when CETP was present (FIG. 10A). However, SNP-induced vasodilatation remained potentiated by Adcy9 inactivation in mice with CETP (P<0.01 for CETPGt versus CETPWT, FIG. 10B). These results suggest that the atheroprotective effect of Adcy9 inactivation in the absence of CETP is associated with their role in the regulation of endothelial function. Example 10: Adcy9 inactivation-induced gains in body weight and adipose tissue volume are lost in mice expressing CETP.
[00416] Quantification of whole body adipose tissue volume by MRI
[00417] Whole mouse MRI was performed in the prone position on a 30 cm 7T horizontal MR scanner (Agilent, Palo Alto, CA), with a 12 cm inner diameter gradient coil insert, gradient strength 600 mT/m, rise-time 130 µs and an Agilent quadrature transmit/receive birdcage coil with an internal diameter of 38 mm. A pressure transducer for respiratory monitoring and gating (used for shimming) was placed under the abdomen near the sternum. Anesthesia was maintained with 2.0-3.0% isoflurane in pure oxygen to target a respiration rate between 80 and 120 BPM while
heart rate and oxygen saturation were monitored with a pulse oximeter on the right hindpaw and body temperature was maintained at 37.0°C with a rectal probe and a warm air fan (SA Instruments, Stony Brook, NY). A 3D TFISP sequence was used to image the whole mouse (except the tail), with isotropic voxels and FOV 70x36x36 mm, matrix size 256x192x192, resolution 270x190x190 µm, an asymmetric 500 µs pulse with 30 degrees flip angle, TR/TE=4.8/2.4 ms, 83 kHz acquisition bandwidth, 8 frequency-shifted scans reconstructed by square-root-of-sum-of- squares, for an acquisition time of 24 minutes. Mouse fat was manually quantified using ITK- SNAP (Yushkevich et al., Neuroimage. (2006) 31:1116-28).
[00418] To further study the interactions between Adcy9 and CETP, the effect of Adcy9 inactivation on body weight change in mice expressing CETP during the atherogenic treatment was investigated. CETPWT and CETPGt mice had similar progression of body weight upon atherogenic treatment (FIG. 11A). At sacrifice, their weights (CETPWT: 34.1±1.1 g; CETPGt: 35.6±1.3 g) were similar to that of WT animals (33.5±1.2 g) and significantly lower than the weight of Adcy9Gt/Gt mice (45.1±2.4 g, P<0.01, FIG. 11A). At week 14, adipose tissue volumes on MRI were similar in CETPWT (4.1±0.5 cm3) and CETPGt mice (5.4±0.7 cm3, FIG.11B). These results demonstrate that Adcy9 and CETP also interact in the regulation of weight and adiposity.
Example 11: Mice model of myocardial infarction
[00419] Mice model of myocardial infarction was generated by ligation of the left ventricular anterior descending (LAD) artery using a suture to mimic the myocardial infarction caused by plague formation (FIG.12B). By closing the LAD, no further blood flow is permitted in that area, while the surrounding myocardial tissue is nearly not affected. This surgical procedure imitates the pathobiological and pathophysiological aspects occurring in infarction-related myocardial ischemia. These mice have four different genotypes: WT (wild-type mice); Adcy9Gt/Gt (Adyc9 gene-trapped mice); tgCETP+/- (transgenic mice carrying a copy of CETP gene); and Adcy9Gt/Gt - tgCETP+/- (Adyc9 gene-trapped mice carrying a copy of CETP gene) (FIG.12A). All mice were in C57BL/6J genetic background. FIG. 12C depicts the surgical timeline of a mouse infarction model by ligating the LAD. Echocardiography (“Echo”) was performed at baseline, at 24 hours, at 1 week, and before 4 weeks postoperatively. The mice were 10±3 week-old at D0 in the timeline.
Example 12: Genotype effects of the mice
[00420] Kruskal-Wallis tests were performed for the age (FIG.13A) and body weight (FIG. 13B) of the mice with the four genotypes: WT (wild-type mice); Adcy9Gt/Gt (Adyc9 gene-trapped mice); tgCETP+/- (transgenic mice carrying a copy of CETP gene); and Adcy9Gt/Gt - tgCETP+/- (Adyc9 gene-trapped mice carrying a copy of CETP gene). No statistically significant differences in the age (FIG.13A) and body weight (FIG.13B) among the mice with the four genotypes were observed.
[00421] Survival of the mice in 28 days were analyzed. No differences in survival among the mice with the four genotypes were observed (FIG.13C).
Example 13: Wall motion score index (WMSI) analysis [00422] Echocardiographic wall motion score index (WMSI) analysis was performed at 24 hours post-LAD-ligation for sham or myocardial-infarction-induced (“MI”) mice with the four genotypes (WT, Adcy9Gt/Gt, tgCETP+/- and Adcy9Gt/Gt - tgCETP+/-). Adcy9Gt/Gt MI mice had a lower WMSI comparing to the mice with the other genotypes. See FIG.14A (all mice) and FIG. 14B (alive mice only). WMSI correlated with serum cardiac troponin‐I (cTn-I) at 24 hours (FIG. 15).
[00423] The reduced WMSI for Adcy9Gt/Gt mice observed at 24 hours post-LAD-ligation is maintained over-time as shown in FIG. 16A. As shown in FIG. 19C, Adcy9Gt/Gt MI mice had a lower WMSI compared to the mice with the other genotypes. FIG.16B shows a two-way repeated ANOVA analysis for myocardial-infarction-induced (“MI”) mice with the four genotypes (WT, Adcy9Gt/Gt, tgCETP+/-, Adcy9Gt/Gt - tgCETP+/-) (p<0.001).
Example 14: Ischemic Myocardium Analysis
[00424] Kruskal-Wallis tests were performed for the portion of ischemic myocaridum of the mice with the four genotypes. The portion of ischemic myocardium was calculated according to FIG.17A. Observation was made at +4 weeks post-LAD-ligation. Proportion of ischemic myocardium is similar among the four genotypes (FIG.17B).
[00425] The hearts of the mice with the four genetic backgrounds were sectioned for histological analysis as illustrated in FIG.18A. Infarct size was estimated with Masson's trichrome staining (FIG. 18B). The infarct sizes of the mice were qualitied for the different sections. The infarct sizes in Adcy9Gt/Gt mice were significantly lower than the infarct sizes in the wild-type and tgCETP+/- mice. The infarct-size-reduction in Adcy9Gt/Gt mice was less pronounced in Adcy9Gt/Gt - tgCETP+/- mice (FIG.19A and FIG.19B). [00426] The entire disclosure of each of the patent documents and scientific publications referred to herein is incorporated by reference for all purposes.
Claims (101)
- WHAT IS CLAIMED IS: 1. A method for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 2. The method of claim 1, wherein administering the CETP inhibitor occurs before, concurrently with, or after administering the ADCY inhibitor.
- 3. The method of claim 1 or 2, wherein the CETP inhibitor is dalcetrapib, torcetrapib,anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 4. The method of claim 1 or 2, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide; 2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 5. The method of any one of claims 1-4, wherein the ADCY inhibitor is an ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 6. The method of any one of claims 1-5, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 7. The method of any one of claims 1-6, wherein the subject is known to have genotypers11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 8. The method of any one of claims 1-6, wherein the subject is known to have genotypers1967309/AA.
- 9. The method of any one of claims 1-6, wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 10. The method of any one of claims 1-6, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 11. A method for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38- 1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 12. A method for treating or preventing congestive heart failure, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 13. The method of claim 11 or 12, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 14. The method of claim 13, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 15. A method for treating or preventing ventricular diastolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 16. The method of claim 15, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 17. The method of claim 15 or 16, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 18. The method of claim 15 or 16, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate; S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 19. The method of any one of claims 15-18, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 20. The method of any one of claims 15-19, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 21. The method of any one of claims 15-20, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 22. The method of any one of claims 15-20, wherein the subject is known to have genotype rs1967309/AA.
- 23. The method of any one of claims 15-20, wherein the subject is known to have genotypers11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 24. The method of any one of claims 15-20, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 25. A method for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 26. The method of claim 25, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 27. The method of claim 25 or 26, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 28. The method of claim 25 or 26, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate; S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 29. The method of any one of claims 25-28, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 30. The method of any one of claims 25-29, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 31. The method of any one of claims 25-30, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 32. The method of any one of claims 25-30, wherein the subject is known to have genotype rs1967309/AA.
- 33. The method of any one of claims 25-30, wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 34. The method of any one of claims 25-30, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 35. A method for treating or preventing ventricular diastolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 36. A method for treating or preventing ventricular diastolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 37. The method of claim 35 or 36, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 38. The method of claim 37, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 39. A method for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP- 800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 40. A method for reducing risk of ventricular diastolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 41. The method of claim 39 or 40, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 42. The method of claim 41, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 43. A method for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of:c) a CETP inhibitor; andd) an ADCY inhibitor.
- 44. The method of claim 43, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 45. The method of claim 43 or 44, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 46. The method of claim 43 or 44, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate; S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 47. The method of any one of claims 43-46, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 48. The method of any one of claims 43-47, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 49. The method of any one of claims 43-48, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 50. The method of any one of claims 43-48, wherein the subject is known to have genotype rs1967309/AA.
- 51. The method of any one of claims 43-48, wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA,rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 52. The method of any one of claims 43-48, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 53. A method for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 54. The method of claim 53, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 55. The method of claim 53 or 54, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 56. The method of claim 53 or 54, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide; 2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 57. The method of any one of claims 53-56, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 58. The method of any one of claims 53-57, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 59. The method of any one of claims 53-58, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 60. The method of any one of claims 53-58, wherein the subject is known to have genotype rs1967309/AA.
- 61. The method of any one of claims 53-58, wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 62. The method of any one of claims 53-58, wherein the subject is known to have genotype rs11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 63. A method for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 64. A method for treating or preventing heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 65. The method of claim 63 or 64, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 66. The method of claim 65, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 67. A method for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 68. A method for reducing risk of heart failure with preserved ejection fraction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 69. The method of claim 67 or 68, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 70. The method of claim 69, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 71. A method for treating or preventing ventricular systolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 72. The method of claim 71, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 73. The method of claim 71 or 72, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 74. The method of claim 71 or 72, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate; S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 75. The method of any one of claims 71-74, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 76. The method of any one of claims 71-75, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 77. The method of any one of claims 71-76, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 78. The method of any one of claims 71-76, wherein the subject is known to have genotype rs1967309/AA.
- 79. The method of any one of claims 71-76, wherein the subject is known to have genotypers11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 80. The method of any one of claims 71-76, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 81. A method for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of:a) a CETP inhibitor; andb) an ADCY inhibitor.
- 82. The method of claim 81, wherein administering the CETP inhibitor occurs before,concurrently with, or after administering the ADCY inhibitor.
- 83. The method of claim 81 or 82, wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL- 17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 84. The method of claim 81 or 82, wherein the CETP inhibitor isS-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate;S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate;S[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2- dimethylthiopropionate;O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate;S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate;S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate;S[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2- dimethylthiopropionate; S[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2- dimethylthiopropionate;S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide;2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide;N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate;S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate;S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate;bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide;N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4- thiocarboxylate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate;S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate;S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; orS-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate, or a pharmaceutically acceptable salt of any of the foregoing.
- 85. The method of any one of claims 81-84, wherein the ADCY inhibitor is an ADCY1,ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, ADCY9 or ADCY10 inhibitor.
- 86. The method of any one of claims 81-85, wherein the ADCY inhibitor is 9-(tetrahydro-2- furanyl)-adenine); 2',5'-dideoxyadenosine; 9-cyclopentyladenine; 2',5'-dideoxyadenosine 3'- diphosphate; 2',5'-dideoxyadenosine 3'-monophosphate; cis-N-(2- phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2- amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4- methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)- quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2- thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT- XTP; MANT-CTP; MANT-UTP; 2’-MANT-3’dATP; 3’-MANT-2’dATP; MANT-ATPgS; MANT-ITPgS; MANT-GTPgS; MANT-UTPgS; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br- ANT-ITP; Pr-ANT-ATP; Pr ANT-ITP; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT- AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP; Bis-MANT-ATP; Bis-MANT-ITP; Bis-MANT-CTP; Bis-MANT-IDP; Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP; Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2’, 5’-dd-3’-ATP; AraAde; PMC6; NB001; BODIPY-FS; 1,9-dd-FS; 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9- Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N¢-(5- bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2¢,5¢-Dideoxyadenosine; 2¢,5¢-Dideoxyadenosine 3¢-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.
- 87. The method of any one of claims 81-86, wherein the subject is known to have genotype rs11647778/CC, rs12595857/GG, rs1967309/AA, rs111590482/AG, rs111590482/GG, rs11647828/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA, rs2238448/TT, rs12920508/GG, rs2531971/AA, or rs12599911/GG.
- 88. The method of any one of claims 81-86, wherein the subject is known to have genotype rs1967309/AA.
- 89. The method of any one of claims 81-86, wherein the subject is known to have genotype rs11647778/CG, rs12595857/AG, rs13337675/AG, rs13337675/GG, rs1967309/AG, rs11647828/AG, rs17136707/AG, rs2239310/AG, rs2283497/CA, rs2531967/GA, rs3730119/GA, rs4786454/GA, rs8049452/GA, rs8061182/AG, rs2238448/TC,rs12920508/CG, rs2531971/AC, or rs12599911/GT.
- 90. The method of any one of claims 81-86, wherein the subject is known to have genotypers11647778/GG, rs12595857/AA, rs13337675/AA, rs1967309/GG, rs111590482/AA, rs11647828/AA, rs12935810/GA, rs12935810/AA, rs17136707/AA, rs2239310/AA, rs2283497/CC, rs2531967/GG, rs3730119/GG, rs4786454/GG, rs74702385/GG,rs8049452/AA, rs8061182/GG, rs2238448/CC, rs12920508/CC, rs2531971/CC, or rs12599911/TT.
- 91. A method for treating or preventing ventricular systolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ- 28614872, BAY 19-4789, BAY 38-1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 92. A method for treating or preventing ventricular systolic dysfunction, comprisingadministering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ- 28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 93. The method of claim 91 or 92, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 94. The method of claim 93, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 95. A method for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY1, ADCY2, ADCY3, ADCY4, ADCY5, ADCY6, ADCY7, ADCY8, or ADCY10, and wherein the CETP inhibitor is dalcetrapib, torcetrapib, anacetrapib, evacetrapib, obicetrapib, BMS795311, CP-800,569, DLBS-1449, ATH-03, DRL-17822, JNJ-28545595, JNJ-28614872, BAY 19-4789, BAY 38- 1315, or BAY 60-5521, or a pharmaceutically acceptable salt of any of the foregoing.
- 96. A method for reducing risk of ventricular systolic dysfunction, comprising administering to a subject in need thereof an effective amount of a CETP inhibitor, wherein the subject is known to have reduced expression or activity level of ADCY compared to a control level, wherein the reduced expression or activity level of ADCY is indicative that the subject would benefit from administration of the CETP inhibitor, wherein the ADCY is ADCY9, and wherein the CETP inhibitor is BMS795311, CP-800,569, JNJ-28545595, JNJ-28614872, BAY 19-4789, or BAY 38-1315, or a pharmaceutically acceptable salt of any of the foregoing.
- 97. The method of claim 95 or 96, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s central nervous system compared to a control level.
- 98. The method of claim 97, wherein the subject is known to have reduced expression or activity level of ADCY in the subject’s hypothalamus compared to a control level.
- 99. The method of any one of claims 1-70, wherein the subject is a human.
- 100. The method of claim 99, wherein the subject is an adult human.
- 101. The method of claim 99, wherein the subject is a pediatric human.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962815068P | 2019-03-07 | 2019-03-07 | |
US62/815,068 | 2019-03-07 | ||
PCT/EP2020/056102 WO2020178443A1 (en) | 2019-03-07 | 2020-03-06 | Methods for treating or preventing heart failure and reducing risk of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020232350A1 true AU2020232350A1 (en) | 2021-07-29 |
Family
ID=69941318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020232350A Abandoned AU2020232350A1 (en) | 2019-03-07 | 2020-03-06 | Methods for treating or preventing heart failure and reducing risk of heart failure |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20210137442A (en) |
AU (1) | AU2020232350A1 (en) |
BR (1) | BR112021014677A2 (en) |
CA (1) | CA3126323A1 (en) |
SG (1) | SG11202107468YA (en) |
WO (1) | WO2020178443A1 (en) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5519001A (en) | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US20030092647A1 (en) * | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
JP4383610B2 (en) | 1999-11-30 | 2009-12-16 | 株式会社東芝 | Nuclear medicine diagnostic equipment |
DOP2005000123A (en) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | CETP INHIBITORS |
CA2635010A1 (en) | 2005-12-30 | 2007-07-19 | Amjad Ali | Oxazolidinone derivatives as cetp inhibitors |
WO2012012870A1 (en) | 2010-07-28 | 2012-02-02 | Institut De Cardiologie De Montreal | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
WO2013075040A1 (en) | 2011-11-16 | 2013-05-23 | The Regents Of The University Of California | Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments |
AU2013346501B2 (en) | 2012-11-19 | 2017-07-13 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of CETP inhibitors |
WO2014128564A2 (en) | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
SI2978859T1 (en) | 2013-03-27 | 2018-10-30 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
WO2016018729A1 (en) | 2014-07-29 | 2016-02-04 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
KR102456013B1 (en) | 2014-07-30 | 2022-10-18 | 에프. 호프만-라 로슈 아게 | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
WO2016086453A1 (en) | 2014-12-04 | 2016-06-09 | 中国药科大学 | Pentacyclic triterpenoid cholesterol ester transfer protein inhibitor, pharmaceutical composition and medical use thereof |
EP3322420B1 (en) | 2015-07-13 | 2021-12-29 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
US20190070178A1 (en) * | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
WO2020030814A1 (en) * | 2018-08-09 | 2020-02-13 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes |
-
2020
- 2020-03-06 WO PCT/EP2020/056102 patent/WO2020178443A1/en active Application Filing
- 2020-03-06 SG SG11202107468YA patent/SG11202107468YA/en unknown
- 2020-03-06 BR BR112021014677-6A patent/BR112021014677A2/en not_active IP Right Cessation
- 2020-03-06 KR KR1020217025686A patent/KR20210137442A/en unknown
- 2020-03-06 AU AU2020232350A patent/AU2020232350A1/en not_active Abandoned
- 2020-03-06 CA CA3126323A patent/CA3126323A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112021014677A2 (en) | 2021-09-28 |
WO2020178443A1 (en) | 2020-09-10 |
KR20210137442A (en) | 2021-11-17 |
SG11202107468YA (en) | 2021-08-30 |
CA3126323A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210290623A1 (en) | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events | |
WO2017143014A1 (en) | Jak inhibitors and uses thereof | |
JP6854766B2 (en) | Compositions and Methods Using Tyrosine Kinase Inhibitors | |
EP3145513B1 (en) | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus | |
OA12554A (en) | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. | |
TW200526224A (en) | Short form c-Maf transcription factor antagonists for treatment of glaucoma | |
WO2020030814A1 (en) | Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes | |
JP2021530491A (en) | Use of sGC stimulants for the treatment of mitochondrial disorders | |
US11957682B2 (en) | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | |
CN116075302A (en) | Combinations of GABAA α5 agonists and SV2A inhibitors and methods of use in the treatment of cognitive impairment | |
AU2022337087A1 (en) | Lou064 for treating multiple sclerosis | |
TW201328695A (en) | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | |
WO2020178443A1 (en) | Methods for treating or preventing heart failure and reducing risk of heart failure | |
EP3119388B1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
US20130324468A1 (en) | METHODS OF TREATING DISEASES ASSOCIATED WITH PPARy | |
US10835532B2 (en) | Muscarinic agonists as cognitive enhancers | |
CN112741904B (en) | Use of Hedgehog signaling pathway inhibitors for treating autism | |
US20190111061A1 (en) | Compositions and methods targeting hcn channels for breathing therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |